Kv11.1
2538 literature references associated to Kv11.1
1
Hirano-Iwata A
et al.
Reconstitution of Human Ion Channels into Solvent-free Lipid Bilayers Enhanced by Centrifugal Forces.
Biophys. J.,
2016
May
24
, 110 (2207-15).
2
Hayashi S
et al.
Discovery of small-molecule nonpeptide antagonists of nociceptin/orphanin FQ receptor: The studies of design, synthesis, and structure-activity relationships for (4-arylpiperidine substituted-methyl)-[bicyclic (hetero)cycloalkanobenzene] derivatives.
Eur J Med Chem,
2016
May
23
, 114 (345-64).
3
Zeng H
et al.
Use of FDSS/μCell imaging platform for preclinical cardiac electrophysiology safety screening of compounds in human induced pluripotent stem cell-derived cardiomyocytes.
J Pharmacol Toxicol Methods,
2016
May
21
, ().
4
Baczkó I
et al.
Rabbit models as tools for preclinical cardiac electrophysiological safety testing: Importance of repolarization reserve.
Prog. Biophys. Mol. Biol.,
2016
May
18
, ().
5
Su Z
et al.
Novel cell-free high-throughput screening method for pharmacological tools targeting K+ channels.
Proc. Natl. Acad. Sci. U.S.A.,
2016
May
17
, 113 (5748-53).
6
Perez-Neut M
et al.
Activation of hERG3 channel stimulates autophagy and promotes cellular senescence in melanoma.
Oncotarget,
2016
Mar
1
, ().
7
Osborne JD
et al.
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).
J. Med. Chem.,
2016
Jun
9
, 59 (5221-37).
8
Zhang X
et al.
Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
J Pharmacol Toxicol Methods,
2016
Jun
7
, ().
9
Colatsky T
et al.
The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.
J Pharmacol Toxicol Methods,
2016
Jun
6
, ().
10
Carbonell-Pascual B
et al.
Comparison between Hodgkin-Huxley and Markov formulations of cardiac ion channels.
J. Theor. Biol.,
2016
Jun
21
, 399 (92-102).
11
Spence S
et al.
Histone Deacetylase Inhibitors Prolong Cardiac Repolarization through Transcriptional Mechanisms.
Toxicol. Sci.,
2016
Jun
2
, ().
12
Șterbuleac D
et al.
An antiarrhythmic agent as a promising lead compound for targeting the hEAG1 ion channel in cancer therapy: insights from molecular dynamics simulations.
Chem Biol Drug Des,
2016
Jun
2
, ().
13
Yamaguchi Y
et al.
Latent pathogenicity of the G38S polymorphism of KCNE1 K(+) channel modulator.
Heart Vessels,
2016
Jun
2
, ().
14
Ng CA
et al.
Tyrosine residues from the S4-S5 linker of Kv11.1 channels are critical for slow deactivation.
J. Biol. Chem.,
2016
Jun
17
, ().
15
Major P
et al.
A novel transgenic rabbit model with reduced repolarization reserve: long QT syndrome caused by a dominant-negative mutation of the KCNE1 gene.
Br. J. Pharmacol.,
2016
Jun
, 173 (2046-61).
16
Wu W
et al.
Molecular Basis of Cardiac Delayed Rectifier Potassium Channel Function and Pharmacology.
Card Electrophysiol Clin,
2016
Jun
, 8 (275-84).
17
Van Driest SL
et al.
Association of Arrhythmia-Related Genetic Variants With Phenotypes Documented in Electronic Medical Records.
JAMA,
2016
Jan
5
, 315 (47-57).
18
Cheng J
et al.
Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.
J. Med. Chem.,
2016
Jan
28
, 59 (578-91).
19
Lee S
et al.
Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
Toxicol. Appl. Pharmacol.,
2016
Jan
25
, ().
20
Yu HB
et al.
Investigation of miscellaneous hERG inhibition in large diverse compound collection using automated patch-clamp assay.
Acta Pharmacol. Sin.,
2016
Jan
, 37 (111-23).
21
Heide J
et al.
Differential Response to Risperidone in Schizophrenia Patients by KCNH2 Genotype and Drug Metabolizer Status.
Am J Psychiatry,
2016
Jan
, 173 (53-9).
22
Bodi I
et al.
Mechanisms of acquired long-QT syndrome in patients with propionic acidemia.
Heart Rhythm,
2016
Feb
5
, ().
23
Neubauer J
et al.
Post-mortem whole-exome sequencing (WES) with a focus on cardiac disease-associated genes in five young sudden unexplained death (SUD) cases.
Int. J. Legal Med.,
2016
Feb
4
, ().
24
Gintant G
et al.
Evolution of strategies to improve preclinical cardiac safety testing.
Nat Rev Drug Discov,
2016
Feb
19
, ().
25
Furtado MB
et al.
A novel conditional mouse model for Nkx2-5 reveals transcriptional regulation of cardiac ion channels.
Differentiation,
2016
Feb
17
, ().
26
Nozaki Y
et al.
CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -Assessment of inter-facility and cells lot-to-lot-variability.
Regul. Toxicol. Pharmacol.,
2016
Feb
13
, ().
27
Crottes D
et al.
SIGMAR1 Regulates Membrane Electrical Activity in Response to Extracellular Matrix Stimulation to Drive Cancer Cell Invasiveness.
Cancer Res.,
2016
Feb
1
, 76 (607-18).
28
Fang P
et al.
[Progress in research on defective protein trafficking and functional restoration in HERG-associated long QT syndrome].
Zhonghua Yi Xue Yi Chuan Xue Za Zhi,
2016
Feb
, 33 (101-4).
29
Crumb WJ
et al.
An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel.
J Pharmacol Toxicol Methods,
2016
Apr
6
, ().
30
Marostica E
et al.
PK/PD Modelling of the QT Interval: a Step Towards Defining the Translational Relationship Between In Vitro, Awake Beagle Dogs, and Humans.
AAPS J,
2016
Apr
26
, ().
31
Liu F
et al.
Cotranslational association of mRNA encoding subunits of heteromeric ion channels.
Proc. Natl. Acad. Sci. U.S.A.,
2016
Apr
26
, 113 (4859-64).
32
Atia J
et al.
Reconstruction of Cell Surface Densities of Ion Pumps, Exchangers, and Channels from mRNA Expression, Conductance Kinetics, Whole-Cell Calcium, and Current-Clamp Voltage Recordings, with an Application to Human Uterine Smooth Muscle Cells.
PLoS Comput. Biol.,
2016
Apr
, 12 (e1004828).
33
Ye F
et al.
The Scorpion Toxin Analogue BmKTX-D33H as a Potential Kv1.3 Channel-Selective Immunomodulator for Autoimmune Diseases.
Toxins (Basel),
2016
, 8 ().
34
Cubeddu LX
Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias.
Curr Cardiol Rev,
2016
, 12 (141-54).
35
Eng G
et al.
Autonomous beating rate adaptation in human stem cell-derived cardiomyocytes.
Nat Commun,
2016
, 7 (10312).
36
Ichikawa M
et al.
Multigenerational Inheritance of Long QT Syndrome Type 2 in a Japanese Family.
Intern. Med.,
2016
, 55 (259-62).
37
Zhao Y
et al.
Regulation of SCN3B/scn3b by Interleukin 2 (IL-2): IL-2 modulates SCN3B/scn3b transcript expression and increases sodium current in myocardial cells.
BMC Cardiovasc Disord,
2016
, 16 (1).
38
Hassinen M
et al.
Molecular basis and drug sensitivity of the delayed rectifier (IKr) in the fish heart.
Comp. Biochem. Physiol. C Toxicol. Pharmacol.,
2015 Oct-Nov
, 176-177 (44-51).
39
Arcangeli A
et al.
Novel perspectives in cancer therapy: Targeting ion channels.
Drug Resist. Updat.,
2015 Jul-Aug
, 21-22 (11-9).
40
Meedech P
et al.
Transmural dispersion of repolarization and cardiac remodeling in ventricles of rabbit with right ventricular hypertrophy.
J Pharmacol Toxicol Methods,
2015 Jan-Feb
, 71 (129-36).
41
Hertz CL
et al.
Genetic investigations of sudden unexpected deaths in infancy using next-generation sequencing of 100 genes associated with cardiac diseases.
Eur. J. Hum. Genet.,
2015
Sep
9
, ().
42
González Cabrera D
et al.
Structure-Activity Relationship Studies of Orally Active Antimalarial 2,4-Diamino-thienopyrimidines.
J. Med. Chem.,
2015
Sep
24
, 58 (7572-9).
43
Salmas RE
et al.
Molecular Simulations of Solved Co-crystallized X-Ray Structures Identify Action Mechanisms of PDEδ Inhibitors.
Biophys. J.,
2015
Sep
15
, 109 (1163-8).
44
Singh SB
et al.
Structure activity relationship of pyridoxazinone substituted RHS analogs of oxabicyclooctane-linked 1,5-naphthyridinyl novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-6).
Bioorg. Med. Chem. Lett.,
2015
Sep
1
, 25 (3636-43).
45
Singh SB
et al.
Structure activity relationship of C-2 ether substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-5).
Bioorg. Med. Chem. Lett.,
2015
Sep
1
, 25 (3630-5).
46
Gupta N
et al.
Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.
Cancer Chemother. Pharmacol.,
2015
Sep
, 76 (507-16).
47
Qu Y
et al.
Proarrhythmia Risk Assessment in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Using the Maestro MEA Platform.
Toxicol. Sci.,
2015
Sep
, 147 (286-95).
48
Farrugia A
et al.
Targeted next generation sequencing application in cardiac channelopathies: Analysis of a cohort of autopsy-negative sudden unexplained deaths.
Forensic Sci. Int.,
2015
Sep
, 254 (5-11).
49
Sheng R
et al.
Novel 1-phenyl-3-hydroxy-4-pyridinone derivatives as Multifunctional Agents for the therapy of Alzheimer's Disease.
ACS Chem Neurosci,
2015
Oct
19
, ().
50
Lees-Miller JP
et al.
In response to Melgari et al. "hERG potassium channel inhibition by ivabradine requires channel gating".
J. Mol. Cell. Cardiol.,
2015
Oct
, 87 (192-3).
51
Melgari D
et al.
hERG potassium channel inhibition by ivabradine requires channel gating.
J. Mol. Cell. Cardiol.,
2015
Oct
, 87 (126-8).
52
Frea S
et al.
New echocardiographic insights in short QT syndrome: More than a channelopathy?
Heart Rhythm,
2015
Oct
, 12 (2096-105).
53
Lee HJ
et al.
Mechanism of inhibition by olanzapine of cloned hERG potassium channels.
Neurosci. Lett.,
2015
Nov
16
, 609 (97-102).
54
Kang Y
et al.
Regulation of the human ether-a-go-go-related gene (hERG) potassium channel by Nedd4 family interacting proteins (Ndfips).
Biochem. J.,
2015
Nov
15
, 472 (71-82).
55
Le Manach C
et al.
A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines.
J. Med. Chem.,
2015
Nov
12
, 58 (8713-22).
56
Zhao H
et al.
Discovery of novel N-aryl piperazine CXCR4 antagonists.
Bioorg. Med. Chem. Lett.,
2015
Nov
1
, 25 (4950-5).
57
Delaunois A
et al.
Cardiac safety of lacosamide: the non-clinical perspective.
Acta Neurol. Scand.,
2015
Nov
, 132 (337-45).
58
Xie S
et al.
Hypaconitine-induced QT prolongation mediated through inhibition of KCNH2 (hERG) potassium channels in conscious dogs.
J Ethnopharmacol,
2015
May
26
, 166 (375-9).
59
Hu N
et al.
High-performance beating pattern function of human induced pluripotent stem cell-derived cardiomyocyte-based biosensors for hERG inhibition recognition.
Biosens Bioelectron,
2015
May
15
, 67 (146-53).
60
Jin SS
et al.
Antiarrhythmic ionic mechanism of Guanfu base A--Selective inhibition of late sodium current in isolated ventricular myocytes from guinea pigs.
Chin J Nat Med,
2015
May
, 13 (361-7).
61
Matus M
et al.
Upregulation of SERCA2a following short-term ACE inhibition (by enalaprilat) alters contractile performance and arrhythmogenicity of healthy myocardium in rat.
Mol. Cell. Biochem.,
2015
May
, 403 (199-208).
62
Leren IS
et al.
Cardiac Mechanical Alterations and Genotype Specific Differences in Subjects With Long QT Syndrome.
JACC Cardiovasc Imaging,
2015
May
, 8 (501-10).
63
Pires NM
et al.
Cardiovascular safety pharmacology profile of etamicastat, a novel peripheral selective dopamine-β-hydroxylase inhibitor.
Eur. J. Pharmacol.,
2015
Mar
5
, 750 (98-107).
64
Kolder IC
et al.
Analysis for Genetic Modifiers of Disease Severity in Patients with Long QT Syndrome Type 2.
Circ Cardiovasc Genet,
2015
Mar
3
, ().
65
Liu Z
et al.
Fluorogenic probe for the human Ether-a-Go-Go-Related Gene potassium channel imaging.
Anal. Chem.,
2015
Mar
3
, 87 (2550-4).
66
Perry MD
et al.
Getting to the heart of hERG K(+) channel gating.
J. Physiol. (Lond.),
2015
Mar
27
, ().
67
Muñoz-Esparza C
et al.
Heterogeneous Phenotype of Long QT Syndrome Caused by the KCNH2-H562R Mutation: Importance of Familial Genetic Testing.
Rev Esp Cardiol (Engl Ed),
2015
Mar
25
, ().
68
Goodchild SJ
et al.
Sequence of gating charge movement and pore gating in HERG activation and deactivation pathways.
Biophys. J.,
2015
Mar
24
, 108 (1435-47).
69
Perissinotti LL
et al.
Kinetic model for NS1643 drug activation of WT and L529I variants of Kv11.1 (hERG1) potassium channel.
Biophys. J.,
2015
Mar
24
, 108 (1414-24).
70
Guo J
et al.
NS1643 interacts around L529 of hERG to alter voltage sensor movement on the path to activation.
Biophys. J.,
2015
Mar
24
, 108 (1400-13).
71
Biliczki P
et al.
The interaction between delayed rectifier channel alpha-subunits does not involve hetero-tetramer formation.
Naunyn Schmiedebergs Arch. Pharmacol.,
2015
Mar
20
, ().
72
Lastraioli E
et al.
hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma.
Br. J. Cancer,
2015
Mar
17
, 112 (1076-87).
73
Villoutreix BO
et al.
Computational investigations of hERG channel blockers: New insights and current predictive models.
Adv. Drug Deliv. Rev.,
2015
Mar
12
, ().
74
Ivanov SM
et al.
Identification of drug targets related to the induction of ventricular tachyarrhythmia through a systems chemical biology approach.
Toxicol. Sci.,
2015
Mar
12
, ().
75
Yang L
et al.
Intravenous anesthetic propofol inhibits multiple human cardiac potassium channels.
Anesthesiology,
2015
Mar
, 122 (571-84).
76
Han SN
et al.
[Effects of midazolam on hERG K+ channel].
Zhongguo Ying Yong Sheng Li Xue Za Zhi,
2015
Mar
, 31 (143-7).
77
Hayashi K
et al.
Functional Characterization of Rare Variants Implicated in Susceptibility to Lone Atrial Fibrillation.
Circ Arrhythm Electrophysiol,
2015
Jun
30
, ().
78
Zhou FJ
et al.
Two New Classes of T-Type Calcium Channel Inhibitors with New Chemical Scaffolds from Ganoderma cochlear.
Org. Lett.,
2015
Jun
19
, 17 (3082-5).
79
Salmas RE
et al.
In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors.
J Enzyme Inhib Med Chem,
2015
Jun
17
, (1-9).
80
Grienke U
et al.
Human Ether-à-go-go Related Gene (hERG) Channel Blocking Aporphine Alkaloids from Lotus Leaves and Their Quantitative Analysis in Dietary Weight Loss Supplements.
J. Agric. Food Chem.,
2015
Jun
17
, 63 (5634-9).
81
Ai Y
et al.
Synthesis and Biological Evaluation of Novel Olean-28,13β-lactams as Potential Antiprostate Cancer Agents.
J. Med. Chem.,
2015
Jun
11
, 58 (4506-20).
82
Wu W
et al.
The Link between Inactivation and High-Affinity Block of hERG1 Channels.
Mol. Pharmacol.,
2015
Jun
, 87 (1042-50).
83
Kurokawa J
et al.
Aromatase knockout mice reveal an impact of estrogen on drug-induced alternation of murine electrocardiography parameters.
J Toxicol Sci,
2015
Jun
, 40 (339-48).
84
Zhao X
et al.
Up-regulation of miR-21 and miR-23a Contributes to As2 O3 -induced hERG Channel Deficiency.
Basic Clin. Pharmacol. Toxicol.,
2015
Jun
, 116 (516-23).
85
Schroder EA
et al.
The cardiomyocyte molecular clock regulates the circadian expression of Kcnh2 and contributes to ventricular repolarization.
Heart Rhythm,
2015
Jun
, 12 (1306-14).
86
Yang LZ
et al.
Urocortin2 prolongs action potential duration and modulates potassium currents in guinea pig myocytes and HEK293 cells.
Eur. J. Pharmacol.,
2015
Jul
5
, 758 (97-106).
87
Stattin EL
et al.
Genetic screening in sudden cardiac death in the young can save future lives.
Int. J. Legal Med.,
2015
Jul
31
, ().
88
Zhang W
et al.
Kcnh2 and Kcnj8 Interactively Regulate Skin Wound Healing and Regeneration.
Wound Repair Regen,
2015
Jul
28
, ().
89
Yue Y
et al.
Pathogenesis of the Novel Autoimmune-Associated Long-QT Syndrome.
Circulation,
2015
Jul
28
, 132 (230-40).
90
De Mieri M
et al.
hERG Channel Inhibitory Daphnane Diterpenoid Orthoesters and Polycephalones A and B with Unprecedented Skeletons from Gnidia polycephala.
J. Nat. Prod.,
2015
Jul
24
, 78 (1697-707).
91
Lee S
et al.
Cellular mechanisms for trazodone-induced cardiotoxicity.
Hum Exp Toxicol,
2015
Jul
17
, ().
92
Fermini B
et al.
A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.
J Biomol Screen,
2015
Jul
13
, ().
93
Harrell DT
et al.
Genotype-dependent differences in age of manifestation and arrhythmia complications in short QT syndrome.
Int. J. Cardiol.,
2015
Jul
1
, 190 (393-402).
94
Gardner A
et al.
C-Linker Accounts for Differential Sensitivity of ERG1 and ERG2 K+ Channels to RPR260243-Induced Slow Deactivation.
Mol. Pharmacol.,
2015
Jul
, 88 (19-28).
95
Issa NP
et al.
QT interval prolongation in a patient with LQT2 on levetiracetam.
Seizure,
2015
Jul
, 29 (134-6).
96
Li L
et al.
Genetic variants of potassium voltage-gated channel genes (KCNQ1, KCNH2, and KCNE1) affected the risk of atrial fibrillation in elderly patients.
Genet Test Mol Biomarkers,
2015
Jul
, 19 (359-65).
97
Wang Y
et al.
Arsenic trioxide inhibits breast cancer cell growth via microRNA-328/hERG pathway in MCF-7 cells.
Mol Med Rep,
2015
Jul
, 12 (1233-8).
98
Wu ZJ
et al.
Characterization of a Chinese KCNQ1 mutation (R259H) that shortens repolarization and causes short QT syndrome 2.
J Geriatr Cardiol,
2015
Jul
, 12 (394-401).
99
Barsanti PA
et al.
Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors.
ACS Med Chem Lett,
2015
Jan
8
, 6 (42-6).
100
Wiśniowska B
et al.
Enhanced QSAR models for drug-triggered inhibition of the main cardiac ion currents.
J Appl Toxicol,
2015
Jan
5
, ().
101
Perez-Neut M
et al.
Stimulation of hERG1 channel activity promotes a calcium-dependent degradation of cyclin E2, but not cyclin E1, in breast cancer cells.
Oncotarget,
2015
Jan
30
, 6 (1631-9).
102
Vedani A
et al.
OpenVirtualToxLab--a platform for generating and exchanging in silico toxicity data.
Toxicol. Lett.,
2015
Jan
22
, 232 (519-32).
103
Saber S
et al.
Complex genetic background in a large family with Brugada syndrome.
Physiol Rep,
2015
Jan
1
, 3 ().
104
Lynch SM
et al.
N-Aryl azacycles as novel sodium channel blockers.
Bioorg. Med. Chem. Lett.,
2015
Jan
1
, 25 (48-52).
105
Riuró H
et al.
Genetic analysis, in silico prediction, and family segregation in long QT syndrome.
Eur. J. Hum. Genet.,
2015
Jan
, 23 (79-85).
106
Xiang F
et al.
Plectasin, first animal toxin-like fungal defensin blocking potassium channels through recognizing channel pore region.
Toxins (Basel),
2015
Jan
, 7 (34-42).
107
Orvos P
et al.
Effects of Chelidonium majus extracts and major alkaloids on hERG potassium channels and on dog cardiac action potential - a safety approach.
Fitoterapia,
2015
Jan
, 100 (156-65).
108
Martin NJ
et al.
Indole alkaloids from the Marquesan plant Rauvolfia nukuhivensis and their effects on ion channels.
Phytochemistry,
2015
Jan
, 109 (84-95).
109
Kubo T
et al.
Phosphatidylinositol4-phosphate 5-kinase prevents the decrease in the HERG potassium current induced by Gq protein-coupled receptor stimulation.
J. Pharmacol. Sci.,
2015
Jan
, 127 (127-34).
110
Chae YJ
et al.
Effects of donepezil on hERG potassium channels.
Brain Res.,
2015
Feb
9
, 1597 (77-85).
111
Wright PD
et al.
A High-Throughput Electrophysiology Assay Identifies Inhibitors of the Inwardly Rectifying Potassium Channel Kir7.1.
J Biomol Screen,
2015
Feb
5
, ().
112
Ellis JM
et al.
Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.
J. Med. Chem.,
2015
Feb
26
, 58 (1929-39).
113
Männikkö R
et al.
Pharmacological and electrophysiological characterisation of hERG activator AZSMO-23.
Br. J. Pharmacol.,
2015
Feb
12
, ().
114
Cheng Y
et al.
An Orally Available BACE1 Inhibitor That Affords Robust CNS Aβ Reduction without Cardiovascular Liabilities.
ACS Med Chem Lett,
2015
Feb
12
, 6 (210-5).
115
Gao Z
et al.
Design and synthesis of a novel series of histamine H3 receptor antagonists through a scaffold hopping strategy.
Bioorg. Med. Chem.,
2015
Feb
1
, 23 (429-38).
116
Vijayvergiya V
et al.
Single channel and ensemble hERG conductance measured in droplet bilayers.
Biomed Microdevices,
2015
Feb
, 17 (12).
117
Zhang H
et al.
Reporting sodium channel activity using calcium flux: pharmacological promiscuity of cardiac Nav1.5.
Mol. Pharmacol.,
2015
Feb
, 87 (207-17).
118
de Llano CT
et al.
Further evidence of the association between LQT syndrome and epilepsy in a family with KCNQ1 pathogenic variant.
Seizure,
2015
Feb
, 25 (65-7).
119
Pulici M
et al.
Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect.
ChemMedChem,
2015
Feb
, 10 (276-95).
120
Gasparoli L
et al.
New pyrimido-indole compound CD-160130 preferentially inhibits the KV11.1B isoform and produces antileukemic effects without cardiotoxicity.
Mol. Pharmacol.,
2015
Feb
, 87 (183-96).
121
Oliván-Viguera A
et al.
A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo.
Mol. Pharmacol.,
2015
Feb
, 87 (338-48).
122
Wu CS
et al.
Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study.
J Am Heart Assoc,
2015
Feb
, 4 ().
123
Yu Z
et al.
Kv 11.1 (hERG)-induced cardiotoxicity: a molecular insight from a binding kinetics study of prototypical Kv 11.1 (hERG) inhibitors.
Br. J. Pharmacol.,
2015
Feb
, 172 (940-55).
124
Zhu W
et al.
Molecular motions that shape the cardiac action potential: Insights from voltage clamp fluorometry.
Prog. Biophys. Mol. Biol.,
2015
Dec
25
, ().
125
Obergrussberger A
et al.
Automated Patch Clamp Meets High-Throughput Screening: 384 Cells Recorded in Parallel on a Planar Patch Clamp Module.
J Lab Autom,
2015
Dec
23
, ().
126
Li X
et al.
Cardiotoxicity screening: a review of rapid-throughput in vitro approaches.
Arch. Toxicol.,
2015
Dec
16
, ().
127
Sviripa VM
et al.
Par-4 secretion: stoichiometry of 3-arylquinoline binding to vimentin.
Org. Biomol. Chem.,
2015
Dec
15
, 14 (74-84).
128
Sundby E
et al.
In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib.
Eur J Pharm Sci,
2015
Dec
1
, 80 (56-65).
129
Robyns T
et al.
Targeted capture sequencing in a large LQTS family reveals a new pathogenic mutation c.2038delG in KCNH2 initially missed due to allelic dropout.
Acta Cardiol,
2015
Dec
, 70 (747-9).
130
Kanters JK
et al.
Combined gating and trafficking defect in Kv11.1 manifests as a malignant long QT syndrome phenotype in a large Danish p.F29L founder family.
Scand. J. Clin. Lab. Invest.,
2015
Dec
, 75 (699-709).
131
Liang D
et al.
[Expression of human ether-a-go-go-related gene in laryngeal carcinoma].
Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi,
2015
Dec
, 29 (2160-3).
132
Zhi D
et al.
The enhancement of cardiac toxicity by concomitant administration of Berberine and macrolides.
Eur J Pharm Sci,
2015
Aug
30
, 76 (149-55).
133
134
Chen J
et al.
Rab11-dependent Recycling of the Human Ether-a-go-go-related Gene (hERG) Channel.
J. Biol. Chem.,
2015
Aug
21
, 290 (21101-13).
135
Oost T
et al.
Design, synthesis and evaluation of MCH receptor 1 antagonists--Part III: Discovery of pre-clinical development candidate BI 186908.
Bioorg. Med. Chem. Lett.,
2015
Aug
15
, 25 (3275-80).
136
Roth GJ
et al.
Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.
Bioorg. Med. Chem. Lett.,
2015
Aug
15
, 25 (3270-4).
137
Yu Z
et al.
Structure-Affinity Relationships (SARs) and Structure-Kinetics Relationships (SKRs) of Kv11.1 Blockers.
J. Med. Chem.,
2015
Aug
13
, 58 (5916-29).
138
Anneken L
et al.
Estradiol regulates human QT-interval: acceleration of cardiac repolarization by enhanced KCNH2 membrane trafficking.
Eur. Heart J.,
2015
Aug
12
, ().
139
Johannesen L
et al.
Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.
Clin. Pharmacol. Ther.,
2015
Aug
11
, ().
140
Marostica E
et al.
Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.
J Pharmacokinet Pharmacodyn,
2015
Aug
11
, ().
141
Deng Q
et al.
Use of molecular modeling aided design to dial out hERG liability in adenosine A(2A) receptor antagonists.
Bioorg. Med. Chem. Lett.,
2015
Aug
1
, 25 (2958-62).
142
Osterbur ML
et al.
An Interdomain KCNH2 Mutation Produces an Intermediate Long QT Syndrome.
Hum. Mutat.,
2015
Aug
, 36 (764-73).
143
Lees-Miller JP
et al.
Ivabradine prolongs phase 3 of cardiac repolarization and blocks the hERG1 (KCNH2) current over a concentration-range overlapping with that required to block HCN4.
J. Mol. Cell. Cardiol.,
2015
Aug
, 85 (71-8).
144
Yasuda C
et al.
The human ether-a-go-go-related gene (hERG) current inhibition selectively prolongs action potential of midmyocardial cells to augment transmural dispersion.
J. Physiol. Pharmacol.,
2015
Aug
, 66 (599-607).
145
Zhang C
et al.
Identification of Low-Risk Adult Congenital LQTS Patients.
J. Cardiovasc. Electrophysiol.,
2015
Aug
, 26 (853-8).
146
Koponen M
et al.
Follow-up of 316 molecularly defined pediatric long-QT syndrome patients: clinical course, treatments, and side effects.
Circ Arrhythm Electrophysiol,
2015
Aug
, 8 (815-23).
147
de la Peña P
et al.
Interactions between the N-terminal tail and the gating machinery of hERG K⁺ channels both in closed and open/inactive states.
Pflugers Arch.,
2015
Aug
, 467 (1747-56).
148
Zhang J
et al.
[Effects of allitridum on rapidly delayed rectifier potassium current in HEK293 cell line].
Nan Fang Yi Ke Da Xue Xue Bao,
2015
Aug
, 35 (1128-32, 1142).
149
Brodney MA
et al.
Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors.
J. Med. Chem.,
2015
Apr
9
, 58 (3223-52).
150
Chae YJ
et al.
Endoxifen, the active metabolite of tamoxifen, inhibits cloned hERG potassium channels.
Eur. J. Pharmacol.,
2015
Apr
5
, 752 (1-7).
151
Williams VS
et al.
Multiplex ligation-dependent probe amplification copy number variant analysis in patients with acquired long QT syndrome.
Europace,
2015
Apr
, 17 (635-41).
152
Erdem M
et al.
herg1b expression as a potential specific marker in pediatric acute myeloid leukemia patients with HERG 897K/K genotype.
Pediatr Hematol Oncol,
2015
Apr
, 32 (182-92).
153
Ferreiro SF
et al.
Acute cardiotoxicity evaluation of the marine biotoxins OA, DTX-1 and YTX.
Toxins (Basel),
2015
Apr
, 7 (1030-47).
154
Melgari D
et al.
hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.
J Am Heart Assoc,
2015
Apr
, 4 ().
155
Wang J
et al.
MiR-133b contributes to arsenic-induced apoptosis in U251 glioma cells by targeting the hERG channel.
J. Mol. Neurosci.,
2015
Apr
, 55 (985-94).
156
Teng G
et al.
Role of mutation and pharmacologic block of human KCNH2 in vasculogenesis and fetal mortality: partial rescue by transforming growth factor-β.
Circ Arrhythm Electrophysiol,
2015
Apr
, 8 (420-8).
157
Han SN
et al.
The protease inhibitor atazanavir blocks hERG K(+) channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane.
Acta Pharmacol. Sin.,
2015
Apr
, 36 (454-62).
158
Obejero-Paz CA
et al.
Quantitative Profiling of the Effects of Vanoxerine on Human Cardiac Ion Channels and its Application to Cardiac Risk.
Sci Rep,
2015
, 5 (17623).
159
Badyra B
et al.
How in vitro influences in silico utilized for the prediction of in vivo - pilot study of the drug-induced pro-arrhythmic potency prediction.
Folia Med Cracov,
2015
, 55 (5-19).
160
161
Chang YS
et al.
Mutation Analysis of KCNQ1, KCNH2 and SCN5A Genes in Taiwanese Long QT Syndrome Patients.
Int Heart J,
2015
, 56 (450-3).
162
Leong IU
et al.
Assessment of the predictive accuracy of five in silico prediction tools, alone or in combination, and two metaservers to classify long QT syndrome gene mutations.
BMC Med. Genet.,
2015
, 16 (34).
163
Stephens RF
et al.
Selectivity filters and cysteine-rich extracellular loops in voltage-gated sodium, calcium, and NALCN channels.
Front Physiol,
2015
, 6 (153).
164
Steffensen AB
et al.
High incidence of functional ion-channel abnormalities in a consecutive Long QT cohort with novel missense genetic variants of unknown significance.
Sci Rep,
2015
, 5 (10009).
165
Stimers JR
et al.
Overexpression of the Large-Conductance, Ca2+-Activated K+ (BK) Channel Shortens Action Potential Duration in HL-1 Cardiomyocytes.
PLoS ONE,
2015
, 10 (e0130588).
166
Pugsley MK
et al.
Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.
Handb Exp Pharmacol,
2015
, 229 (149-203).
167
Hisajima N
et al.
The Susceptibilities of Human Ether-à-Go-Go-Related Gene Channel with the G487R Mutation to Arrhythmogenic Factors.
Biol. Pharm. Bull.,
2015
, 38 (781-4).
168
Martelli A
et al.
Inhibitors of the renal outer medullary potassium channel: a patent review.
Expert Opin Ther Pat,
2015
, 25 (1035-51).
169
Shi YQ
et al.
Mechanisms underlying probucol-induced hERG-channel deficiency.
Drug Des Devel Ther,
2015
, 9 (3695-704).
170
Molbaek K
et al.
High yield purification of full-length functional hERG K+ channels produced in Saccharomyces cerevisiae.
Microb. Cell Fact.,
2015
, 14 (15).
171
Okada M
et al.
Increase in the titer of lentiviral vectors expressing potassium channels by current blockade during viral vector production.
BMC Neurosci,
2015
, 16 (30).
172
Allegue C
et al.
Genetic Analysis of Arrhythmogenic Diseases in the Era of NGS: The Complexity of Clinical Decision-Making in Brugada Syndrome.
PLoS ONE,
2015
, 10 (e0133037).
173
Shi YQ
et al.
High Glucose Represses hERG K+ Channel Expression through Trafficking Inhibition.
Cell. Physiol. Biochem.,
2015
, 37 (284-96).
174
Lastraioli E
et al.
hERG1 Potassium Channels: Novel Biomarkers in Human Solid Cancers.
Biomed Res Int,
2015
, 2015 (896432).
175
Giacomini E
et al.
A ligand-based virtual screening approach to identify small molecules as HERG channel activators.
Comb. Chem. High Throughput Screen.,
2015
, 18 (269-80).
176
Pedersen PJ
et al.
Molecular Cloning and Functional Expression of the Equine K+ Channel KV11.1 (Ether à Go-Go-Related/KCNH2 Gene) and the Regulatory Subunit KCNE2 from Equine Myocardium.
PLoS ONE,
2015
, 10 (e0138320).
177
Ji N
et al.
Effect of celastrol on growth inhibition of prostate cancer cells through the regulation of hERG channel in vitro.
Biomed Res Int,
2015
, 2015 (308475).
178
Dey D
et al.
Acute and chronic toxicity, cytochrome p450 enzyme inhibition, and HERG channel blockade studies with a polyherbal, ayurvedic formulation for inflammation.
Biomed Res Int,
2015
, 2015 (971982).
179
Jing Y
et al.
In silico prediction of hERG inhibition.
Future Med Chem,
2015
, 7 (571-86).
180
Liu QN
et al.
Eag Domains Regulate LQT Mutant hERG Channels in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
PLoS ONE,
2015
, 10 (e0123951).
181
Du F
et al.
Global analysis reveals families of chemical motifs enriched for HERG inhibitors.
PLoS ONE,
2015
, 10 (e0118324).
182
Vonderlin N
et al.
Anesthetic drug midazolam inhibits cardiac human ether-à-go-go-related gene channels: mode of action.
Drug Des Devel Ther,
2015
, 9 (867-77).
183
Wu W
et al.
Concatenated hERG1 tetramers reveal stoichiometry of altered channel gating by RPR-260243.
Mol. Pharmacol.,
2015
, 87 (401-9).
184
Vicente J
et al.
Comprehensive T wave Morphology Assessment in a Randomized Clinical Study of Dofetilide, Quinidine, Ranolazine, and Verapamil.
J Am Heart Assoc,
2015
, 4 ().
185
Rast G
et al.
Solubility assessment and on-line exposure confirmation in a patch-clamp assay for hERG (human ether-a-go-go-related gene) potassium channel inhibition.
J Pharmacol Toxicol Methods,
2014 Sep-Oct
, 70 (182-7).
186
Gibson JK
et al.
Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents.
J Pharmacol Toxicol Methods,
2014 Nov-Dec
, 70 (255-67).
187
Mirams GR
et al.
Prediction of Thorough QT study results using action potential simulations based on ion channel screens.
J Pharmacol Toxicol Methods,
2014 Nov-Dec
, 70 (246-54).
188
Rodríguez-Menchaca AA
et al.
Impact of the whole-cell patch-clamp configuration on the pharmacological assessment of the hERG channel: trazodone as a case example.
J Pharmacol Toxicol Methods,
2014 May-Jun
, 69 (237-44).
189
Kim TW
et al.
Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies.
J Pharmacol Toxicol Methods,
2014 Jan-Feb
, 69 (49-60).
190
Cai Y
et al.
Down-regulation of ether-a-go-go-related gene potassium channel protein through sustained stimulation of AT1 receptor by angiotensin II.
Biochem. Biophys. Res. Commun.,
2014
Sep
26
, 452 (852-7).
191
Washburn WN
et al.
Identification of a nonbasic melanin hormone receptor 1 antagonist as an antiobesity clinical candidate.
J. Med. Chem.,
2014
Sep
25
, 57 (7509-22).
192
Brudeli B
et al.
Discovery and pharmacological profile of new hydrophilic 5-HT(4) receptor antagonists.
Bioorg. Med. Chem. Lett.,
2014
Sep
15
, 24 (4598-602).
193
Ng CA
et al.
Multiple interactions between cytoplasmic domains regulate slow deactivation of Kv11.1 channels.
J. Biol. Chem.,
2014
Sep
12
, 289 (25822-32).
194
Shopp GM
et al.
Liposomes ameliorate Crizotinib- and Nilotinib-induced inhibition of the cardiac IKr channel and QTc prolongation.
Anticancer Res.,
2014
Sep
, 34 (4733-40).
195
Han SN
et al.
Identification and functional characterization of the human ether-a-go-go-related gene Q738X mutant associated with hereditary long QT syndrome type 2.
Int. J. Mol. Med.,
2014
Sep
, 34 (810-5).
196
Choi SH
et al.
Ginseng gintonin activates the human cardiac delayed rectifier K+ channel: involvement of Ca2+/calmodulin binding sites.
Mol. Cells,
2014
Sep
, 37 (656-63).
197
Bartok A
et al.
Margatoxin is a non-selective inhibitor of human Kv1.3 K(+) channels.
Toxicon,
2014
Sep
, 87 (6-16).
198
Kim Y
et al.
Novel thienopyrimidinones as mGluR1 antagonists.
Eur J Med Chem,
2014
Oct
6
, 85 (629-37).
199
Kauthale RR
et al.
Assessment of temperature-induced hERG channel blockade variation by drugs.
J Appl Toxicol,
2014
Oct
28
, ().
200
Kratz JM
et al.
Experimentally validated HERG pharmacophore models as cardiotoxicity prediction tools.
J Chem Inf Model,
2014
Oct
27
, 54 (2887-901).
201
Comer E
et al.
Diversity-oriented synthesis-facilitated medicinal chemistry: toward the development of novel antimalarial agents.
J. Med. Chem.,
2014
Oct
23
, 57 (8496-502).
202
Perlmutter JI
et al.
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
J. Med. Chem.,
2014
Oct
23
, 57 (8540-62).
203
Patanè S
HERG-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs.
Int. J. Cardiol.,
2014
Oct
20
, 176 (1082-5).
204
Nogawa H
et al.
hERG trafficking inhibition in drug-induced lethal cardiac arrhythmia.
Eur. J. Pharmacol.,
2014
Oct
15
, 741 (336-9).
205
Olde Nordkamp LR
et al.
Syncope in genotype-negative long QT syndrome family members.
Am. J. Cardiol.,
2014
Oct
15
, 114 (1223-8).
206
Wu W
et al.
Cooperative subunit interactions mediate fast C-type inactivation of hERG1 K+ channels.
J. Physiol. (Lond.),
2014
Oct
15
, 592 (4465-80).
207
Reck F
et al.
Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa.
Bioorg. Med. Chem.,
2014
Oct
1
, 22 (5392-409).
208
Hull CM
et al.
Regional flexibility in the S4-S5 linker regulates hERG channel closed-state stabilization.
Pflugers Arch.,
2014
Oct
, 466 (1911-9).
209
Terentyev D
et al.
Hyperphosphorylation of RyRs underlies triggered activity in transgenic rabbit model of LQT2 syndrome.
Circ. Res.,
2014
Nov
7
, 115 (919-28).
210
Anwar-Mohamed A
et al.
A human ether-á-go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity.
Toxicol. Lett.,
2014
Nov
4
, 230 (382-92).
211
Linder T
et al.
Structural insights into trapping and dissociation of small molecules in K⁺ channels.
J Chem Inf Model,
2014
Nov
24
, 54 (3218-28).
212
Colenso CK
et al.
Voltage sensor gating charge transfer in a hERG potassium channel model.
Biophys. J.,
2014
Nov
18
, 107 (L25-8).
213
Balasuriya D
et al.
A direct interaction between the sigma-1 receptor and the hERG voltage-gated K+ channel revealed by atomic force microscopy and homogeneous time-resolved fluorescence (HTRF®).
J. Biol. Chem.,
2014
Nov
14
, 289 (32353-63).
214
Scott JS
et al.
Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists.
J. Med. Chem.,
2014
Nov
13
, 57 (8984-98).
215
Le Manach C
et al.
Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a softfocus kinase library: part 2.
J. Med. Chem.,
2014
Nov
13
, 57 (8839-48).
216
Jensen JE
et al.
Understanding the molecular basis of toxin promiscuity: the analgesic sea anemone peptide APETx2 interacts with acid-sensing ion channel 3 and hERG channels via overlapping pharmacophores.
J. Med. Chem.,
2014
Nov
13
, 57 (9195-203).
217
Nikolov NG
et al.
hERG blocking potential of acids and zwitterions characterized by three thresholds for acidity, size and reactivity.
Bioorg. Med. Chem.,
2014
Nov
1
, 22 (6004-13).
218
Luo F
et al.
Molecular docking and molecular dynamics studies on the structure-activity relationship of fluoroquinolone for the HERG channel.
Mol Biosyst,
2014
Nov
, 10 (2863-9).
219
Gong Q
et al.
Upregulation of functional Kv11.1 isoform expression by inhibition of intronic polyadenylation with antisense morpholino oligonucleotides.
J. Mol. Cell. Cardiol.,
2014
Nov
, 76 (26-32).
220
Loewe A
et al.
In-silico assessment of the dynamic effects of amiodarone and dronedarone on human atrial patho-electrophysiology.
Europace,
2014
Nov
, 16 Suppl 4 (iv30-iv38).
221
Zhao X
et al.
The rescuable function and mechanism of resveratrol on As₂O₃-induced hERG K⁺ channel deficiency.
Naunyn Schmiedebergs Arch. Pharmacol.,
2014
Nov
, 387 (1079-89).
222
Johannesen L
et al.
Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil.
Clin. Pharmacol. Ther.,
2014
Nov
, 96 (549-58).
223
Frolov RV
et al.
Celecoxib and ion channels: a story of unexpected discoveries.
Eur. J. Pharmacol.,
2014
May
5
, 730 (61-71).
224
Shi S
et al.
Chronic N-Methyl-d-Aspartate Receptor Activation Induces Cardiac Electrical Remodeling and Increases Susceptibility to Ventricular Arrhythmias.
Pacing Clin Electrophysiol,
2014
May
30
, ().
225
Ke Y
et al.
Role of the cytoplasmic N-terminal Cap and Per-Arnt-Sim (PAS) domain in trafficking and stabilization of Kv11.1 channels.
J. Biol. Chem.,
2014
May
16
, 289 (13782-91).
226
Pier DM
et al.
Long-term Channel Block is Required to Inhibit Cellular Transformation by Human Ether-a-go-go-related Gene (Herg1) Potassium Channels.
Mol. Pharmacol.,
2014
May
15
, ().
227
Wang S
et al.
β1-adrenergic regulation of rapid component of delayed rectifier K+ currents in guinea-pig cardiac myocytes.
Mol Med Rep,
2014
May
, 9 (1923-8).
228
Wang Q
et al.
Gain-of-function KCNH2 mutations in patients with Brugada syndrome.
J. Cardiovasc. Electrophysiol.,
2014
May
, 25 (522-30).
229
Hill AP
et al.
Kinetics of drug interaction with the Kv11.1 potassium channel.
Mol. Pharmacol.,
2014
May
, 85 (769-76).
230
231
Crociani O
et al.
hERG1 channels regulate VEGF-A secretion in human gastric cancer: clinicopathological correlations and therapeutical implications.
Clin. Cancer Res.,
2014
Mar
15
, 20 (1502-12).
232
Schumacher-Bass SM
et al.
Role for myosin-V motor proteins in the selective delivery of Kv channel isoforms to the membrane surface of cardiac myocytes.
Circ. Res.,
2014
Mar
14
, 114 (982-92).
233
Bhuiyan ZA
et al.
Not all pathogenic mutations are pathogenic: KCNH2 mutations in two sisters with tetralogy of Fallot.
Int. J. Cardiol.,
2014
Mar
1
, 172 (276-7).
234
Koenig X
et al.
Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk.
Addict Biol,
2014
Mar
, 19 (237-9).
235
Rodríguez-Ravelo R
et al.
A K⁺ channel blocking peptide from the Cuban scorpion Rhopalurus garridoi.
Peptides,
2014
Mar
, 53 (42-7).
236
Yu H
et al.
Comparison of read-through effects of aminoglycosides and PTC124 on rescuing nonsense mutations of HERG gene associated with long QT syndrome.
Int. J. Mol. Med.,
2014
Mar
, 33 (729-35).
237
Yang Y
et al.
[Construction of pcDNA3-HERG-G572R expression vector and establishment of a cell line stably expressing HKE-HERG-G572R].
Nan Fang Yi Ke Da Xue Xue Bao,
2014
Mar
, 34 (308-11).
238
Young JC
The role of the cytosolic HSP70 chaperone system in diseases caused by misfolding and aberrant trafficking of ion channels.
Dis Model Mech,
2014
Mar
, 7 (319-29).
239
Pond AL
et al.
The mERG1a channel modulates skeletal muscle MuRF1, but not MAFbx, expression.
Muscle Nerve,
2014
Mar
, 49 (378-88).
240
Loewe A
et al.
Arrhythmic potency of human ether-a-go-go-related gene mutations L532P and N588K in a computational model of human atrial myocytes.
Europace,
2014
Mar
, 16 (435-43).
241
Baumgartner S
et al.
Electrophysiological and Morphological Maturation of Murine Fetal Cardiomyocytes During Electrical Stimulation In Vitro.
J. Cardiovasc. Pharmacol. Ther.,
2014
Jun
9
, ().
242
Priest JR
et al.
Molecular Diagnosis of Long-QT syndrome at 10 Days of Life by Rapid Whole Genome Sequencing.
Heart Rhythm,
2014
Jun
25
, ().
243
Coleman N
et al.
New Positive KCa Channel Gating Modulators with Selectivity for KCa3.1.
Mol. Pharmacol.,
2014
Jun
23
, ().
244
Sviripa VM
et al.
2',6'-Dihalostyrylanilines, Pyridines and Pyrimidines for the Inhibition of the Catalytic Subunit of Methionine S-Adenosyltransferase-2 (MAT2A).
J. Med. Chem.,
2014
Jun
20
, ().
245
Hameed P S
et al.
Novel N-Linked Aminopiperidine-Based Gyrase Inhibitors with Improved hERG and in Vivo Efficacy against Mycobacterium tuberculosis.
J. Med. Chem.,
2014
Jun
12
, 57 (4889-905).
246
Li Q
et al.
Insight into the molecular interaction between the cyclic nucleotide-binding homology domain and the eag domain of the hERG channel.
FEBS Lett.,
2014
Jun
12
, ().
247
Mehta A
et al.
Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes.
Cardiovasc. Res.,
2014
Jun
1
, 102 (497-506).
248
Wang T
et al.
Muscarinic receptor activation increases hERG channel expression through phosphorylation of ubiquitin ligase Nedd4-2.
Mol. Pharmacol.,
2014
Jun
, 85 (877-86).
249
Moorthy NS
et al.
Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blockers using newer tools.
J Enzyme Inhib Med Chem,
2014
Jun
, 29 (317-24).
250
Pillozzi S
et al.
Differential expression of hERG1A and hERG1B genes in pediatric acute lymphoblastic leukemia identifies different prognostic subgroups.
Leukemia,
2014
Jun
, 28 (1352-5).
251
Feng J
et al.
HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96.
Oncotarget,
2014
Jul
30
, 5 (5832-44).
252
Sherhod R
et al.
Emerging pattern mining to aid toxicological knowledge discovery.
J Chem Inf Model,
2014
Jul
28
, 54 (1864-79).
253
Romero L
et al.
In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome.
J. Mol. Cell. Cardiol.,
2014
Jul
, 72 (126-37).
254
Bando S
et al.
Congenital long QT syndrome with compound mutations in the KCNH2 gene.
Heart Vessels,
2014
Jul
, 29 (554-9).
255
Glengarry JM
et al.
Long QT molecular autopsy in sudden infant death syndrome.
Arch. Dis. Child.,
2014
Jul
, 99 (635-40).
256
Luna-Ramírez K
et al.
Structure, molecular modeling, and function of the novel potassium channel blocker urotoxin isolated from the venom of the Australian scorpion Urodacus yaschenkoi.
Mol. Pharmacol.,
2014
Jul
, 86 (28-41).
257
González Cabrera D
et al.
2,4-Diaminothienopyrimidines as Orally Active Antimalarial Agents.
J. Med. Chem.,
2014
Jan
28
, ().
258
Radresa O
et al.
Roles of PKC Isoforms in PMA-Induced Modulation of the hERG Channel (Kv11.1).
J Biomol Screen,
2014
Jan
24
, ().
259
Gohlke BO
et al.
SuperPain--a resource on pain-relieving compounds targeting ion channels.
Nucleic Acids Res.,
2014
Jan
1
, 42 (D1107-12).
260
Yu Z
et al.
Allosteric modulators of the hERG K(+) channel: Radioligand binding assays reveal allosteric characteristics of dofetilide analogs.
Toxicol. Appl. Pharmacol.,
2014
Jan
1
, 274 (78-86).
261
Du D
et al.
In-silico modeling of glycosylation modulation dynamics in HERG ion channels and cardiac electrical signals.
IEEE J Biomed Health Inform,
2014
Jan
, 18 (205-14).
262
Chen A
et al.
Integrated platform for functional monitoring of biomimetic heart sheets derived from human pluripotent stem cells.
Biomaterials,
2014
Jan
, 35 (675-83).
263
Hata Y
et al.
Identification and characterization of a novel genetic mutation with prolonged QT syndrome in an unexplained postoperative death.
Int. J. Legal Med.,
2014
Jan
, 128 (105-15).
264
Schulze V
et al.
The opioid methadone induces a local anaesthetic-like inhibition of the cardiac Na⁺ channel, Na(v)1.5.
Br. J. Pharmacol.,
2014
Jan
, 171 (427-37).
265
Mints Y
et al.
Single nucleotide polymorphisms in proximity to K-channel genes are associated with decreased longitudinal QTc variance.
Ann Noninvasive Electrocardiol,
2014
Jan
, 19 (63-9).
266
Dempsey CE
et al.
Assessing hERG pore models as templates for drug docking using published experimental constraints: the inactivated state in the context of drug block.
J Chem Inf Model,
2014
Feb
24
, 54 (601-12).
267
Nair AG
et al.
IV. Discovery of CXCR3 antagonists substituted with heterocycles as amide surrogates: improved PK, hERG and metabolic profiles.
Bioorg. Med. Chem. Lett.,
2014
Feb
15
, 24 (1085-8).
268
Choi YJ
et al.
Successful reduction of off-target hERG toxicity by structural modification of a T-type calcium channel blocker.
Bioorg. Med. Chem. Lett.,
2014
Feb
1
, 24 (880-3).
269
Shin DS
et al.
A novel assessment of nefazodone-induced hERG inhibition by electrophysiological and stereochemical method.
Toxicol. Appl. Pharmacol.,
2014
Feb
1
, 274 (361-71).
270
Thurner P
et al.
Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine.
J. Pharmacol. Exp. Ther.,
2014
Feb
, 348 (346-58).
271
Ma Q
et al.
Screening for cardiac HERG potassium channel interacting proteins using the yeast two-hybrid technique.
Cell Biol. Int.,
2014
Feb
, 38 (239-45).
272
Ferreiro SF
et al.
In vivo arrhythmogenicity of the marine biotoxin azaspiracid-2 in rats.
Arch. Toxicol.,
2014
Feb
, 88 (425-34).
273
Zhang Y
et al.
The SCN5A mutation A1180V is associated with electrocardiographic features of LQT3.
Pediatr Cardiol,
2014
Feb
, 35 (295-300).
274
Roder K
et al.
RING finger protein RNF207, a novel regulator of cardiac excitation.
J. Biol. Chem.,
2014
Dec
5
, 289 (33730-40).
275
Jones DK
et al.
hERG 1b is critical for human cardiac repolarization.
Proc. Natl. Acad. Sci. U.S.A.,
2014
Dec
16
, 111 (18073-7).
276
Ogiyama T
et al.
Discovery of novel tetrahydroisoquinoline derivatives as orally active N-type calcium channel blockers with high selectivity for hERG potassium channels.
Bioorg. Med. Chem.,
2014
Dec
15
, 22 (6899-907).
277
Lim CJ
et al.
Synthesis and SAR of thieno[3,2-b]pyridinyl urea derivatives as urotensin-II receptor antagonists.
Bioorg. Med. Chem. Lett.,
2014
Dec
15
, 24 (5832-5).
278
Harcken C
et al.
Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.
ACS Med Chem Lett,
2014
Dec
11
, 5 (1318-23).
279
Epstein O
et al.
Lead optimization and modulation of hERG activity in a series of aminooxazoline xanthene β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.
J. Med. Chem.,
2014
Dec
11
, 57 (9796-810).
280
Dineen TA
et al.
Inhibitors of β-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine (AMG-8718).
J. Med. Chem.,
2014
Dec
11
, 57 (9811-31).
281
Strauss KA
et al.
A population-based study of KCNH7 p.Arg394His and bipolar spectrum disorder.
Hum. Mol. Genet.,
2014
Dec
1
, 23 (6395-406).
282
Bond R
et al.
Congenital long QT syndrome: a case report of LQT2 and LQT13 in a neonate.
Europace,
2014
Dec
, 16 (1807).
283
Ferreiro SF
et al.
In vitro chronic effects on hERG channel caused by the marine biotoxin azaspiracid-2.
Toxicon,
2014
Dec
, 91 (69-75).
284
Lin EC
et al.
Mouse ERG K(+) channel clones reveal differences in protein trafficking and function.
J Am Heart Assoc,
2014
Dec
, 3 (e001491).
285
Zhang KP
et al.
Translational toxicology and rescue strategies of the hERG channel dysfunction: biochemical and molecular mechanistic aspects.
Acta Pharmacol. Sin.,
2014
Dec
, 35 (1473-84).
286
Li Q
et al.
Structural insight into the transmembrane segments 3 and 4 of the hERG potassium channel.
J. Pept. Sci.,
2014
Dec
, 20 (935-44).
287
Li P
et al.
The human ether-a-go-go-related gene activator NS1643 enhances epilepsy-associated KCNQ channels.
J. Pharmacol. Exp. Ther.,
2014
Dec
, 351 (596-604).
288
Wang Y
et al.
Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing.
J. Am. Coll. Cardiol.,
2014
Aug
5
, 64 (451-9).
289
Schmidtke P
et al.
Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
J Chem Inf Model,
2014
Aug
25
, 54 (2320-33).
290
Thomson SJ
et al.
Concerted all-or-none subunit interactions mediate slow deactivation of human ether-à-go-go-related gene K+ channels.
J. Biol. Chem.,
2014
Aug
22
, 289 (23428-36).
291
Long Y
et al.
Inhibition of HERG potassium channels by domiphen bromide and didecyl dimethylammonium bromide.
Eur. J. Pharmacol.,
2014
Aug
15
, 737 (202-9).
292
Cid JM
et al.
Discovery of 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): a novel positive allosteric modulator of the metabotropic glutamate 2 receptor.
J. Med. Chem.,
2014
Aug
14
, 57 (6495-512).
293
Spencer CI
et al.
Calcium transients closely reflect prolonged action potentials in iPSC models of inherited cardiac arrhythmia.
Stem Cell Reports,
2014
Aug
12
, 3 (269-81).
294
Hajj A
et al.
KCNH2 polymorphism and methadone dosage interact to enhance QT duration.
Drug Alcohol Depend,
2014
Aug
1
, 141 (34-8).
295
Yun J
et al.
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
Bioorg. Med. Chem. Lett.,
2014
Aug
1
, 24 (3234-7).
296
Imai M
et al.
Novel KCNQ1 splicing mutation in patients with forme fruste LQT1 aggravated by hypokalemia.
J Cardiol,
2014
Aug
, 64 (121-6).
297
Liu LL
et al.
Novel Bayesian classification models for predicting compounds blocking hERG potassium channels.
Acta Pharmacol. Sin.,
2014
Aug
, 35 (1093-102).
298
Alexandrou AJ
et al.
The human ether-a'-go-go related gene (hERG) K+ channel blockade by the investigative selective-serotonin reuptake inhibitor CONA-437: limited dependence on S6 aromatic residues.
J. Physiol. Pharmacol.,
2014
Aug
, 65 (511-23).
299
Gong Q
et al.
Identification of Kv11.1 isoform switch as a novel pathogenic mechanism of long-QT syndrome.
Circ Cardiovasc Genet,
2014
Aug
, 7 (482-90).
300
Gong Q
et al.
Position of premature termination codons determines susceptibility of hERG mutations to nonsense-mediated mRNA decay in long QT syndrome.
Gene,
2014
Apr
15
, 539 (190-7).
301
Weeke P
et al.
Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome.
J. Am. Coll. Cardiol.,
2014
Apr
15
, 63 (1430-7).
302
Martinson AS
et al.
Functional evolution of Erg potassium channel gating reveals an ancient origin for IKr.
Proc. Natl. Acad. Sci. U.S.A.,
2014
Apr
15
, 111 (5712-7).
303
Chanséaume A
et al.
[KCNH2 gene new mutation in a patient with prior diagnosis of epilepsy].
Rev. Neurol. (Paris),
2014
Apr
, 170 (304-5).
305
Noriega-Navarro R
et al.
Novel TASK channels inhibitors derived from dihydropyrrolo[2,1-a]isoquinoline.
Neuropharmacology,
2014
Apr
, 79 (28-36).
306
Silvestre JS
et al.
Evidence for a crucial modulating role of the sodium channel in the QTc prolongation related to antipsychotics.
J. Psychopharmacol. (Oxford),
2014
Apr
, 28 (329-40).
307
Sanguinetti MC
HERG1 channel agonists and cardiac arrhythmia.
Curr Opin Pharmacol,
2014
Apr
, 15 (22-7).
308
Wu W
et al.
Stoichiometry of altered hERG1 channel gating by small molecule activators.
J. Gen. Physiol.,
2014
Apr
, 143 (499-512).
309
Wang D
et al.
Cardiac channelopathy testing in 274 ethnically diverse sudden unexplained deaths.
Forensic Sci. Int.,
2014
Apr
, 237 (90-9).
310
Tester DJ
et al.
GENETICS OF LONG QT SYNDROME.
Methodist Debakey Cardiovasc J,
2014
1
, 10 (29-33).
311
Zhang P
et al.
New Aspects of HERG K(+) Channel Function Depending upon Cardiac Spatial Heterogeneity.
PLoS ONE,
2014
, 9 (e72181).
312
Iyer V
et al.
Modeling Tissue- and Mutation- Specific Electrophysiological Effects in the Long QT Syndrome: Role of the Purkinje Fiber.
PLoS ONE,
2014
, 9 (e97720).
313
Sivagangabalan G
et al.
Regional ion channel gene expression heterogeneity and ventricular fibrillation dynamics in human hearts.
PLoS ONE,
2014
, 9 (e82179).
314
Shao XD
et al.
The mechanism of COX-2 regulating HERG channel in gastric cancer cells.
Bratisl Lek Listy,
2014
, 115 (487-91).
315
Zheng X
et al.
Natural antisense transcripts regulate the neuronal stress response and excitability.
Elife,
2014
, 3 (e01849).
316
Christiansen M
et al.
Mutations in Danish patients with long QT syndrome and the identification of a large founder family with p.F29L in KCNH2.
BMC Med. Genet.,
2014
, 15 (31).
317
Durdagi S
et al.
Rehabilitating drug-induced long-QT promoters: in-silico design of hERG-neutral cisapride analogues with retained pharmacological activity.
BMC Pharmacol Toxicol,
2014
, 15 (14).
318
Schlichter LC
et al.
Regulation of hERG and hEAG channels by Src and by SHP-1 tyrosine phosphatase via an ITIM region in the cyclic nucleotide binding domain.
PLoS ONE,
2014
, 9 (e90024).
319
Munoz C
et al.
Up-regulation of Kir2.1 (KCNJ2) by the serum & glucocorticoid inducible SGK3.
Cell. Physiol. Biochem.,
2014
, 33 (491-500).
320
Rizzo A
et al.
Identification of novel RHPS4-derivative ligands with improved toxicological profiles and telomere-targeting activities.
J. Exp. Clin. Cancer Res.,
2014
, 33 (81).
321
Shimizu W
Clinical and genetic diagnosis for inherited cardiac arrhythmias.
J Nippon Med Sch,
2014
, 81 (203-10).
322
Aslanidis A
et al.
RETINA-specific expression of Kcnv2 is controlled by cone-rod homeobox (Crx) and neural retina leucine zipper (Nrl).
Adv. Exp. Med. Biol.,
2014
, 801 (31-41).
323
Jimmy JJ
et al.
Clinical characteristics of patients with congenital long QT syndrome and bigenic mutations.
Chin. Med. J.,
2014
, 127 (1482-6).
324
Polonchuk L
Industrializing electrophysiology: HT automated patch clamp on SyncroPatch® 96 using instant frozen cells.
Methods Mol. Biol.,
2014
, 1183 (81-92).
325
Danker T
et al.
Early identification of hERG liability in drug discovery programs by automated patch clamp.
Front Pharmacol,
2014
, 5 (203).
326
Braga RC
et al.
Tuning HERG out: antitarget QSAR models for drug development.
Curr Top Med Chem,
2014
, 14 (1399-415).
327
Staudacher I
et al.
HERG K+ channel-dependent apoptosis and cell cycle arrest in human glioblastoma cells.
PLoS ONE,
2014
, 9 (e88164).
328
Li G
et al.
Allitridin reduces I Kr current by disrupting the trafficking of human ether-à-go-go-related gene channels.
Cardiology,
2014
, 128 (1-8).
329
Pakladok T
et al.
Up-regulation of hERG K⁺ channels by B-RAF.
PLoS ONE,
2014
, 9 (e87457).
330
Yamaguchi Y
et al.
Glycine/Serine polymorphism at position 38 influences KCNE1 subunit's modulatory actions on rapid and slow delayed rectifier K+ currents.
Circ. J.,
2014
, 78 (610-8).
331
Hu YT
et al.
Open conformation of hERG channel turrets revealed by a specific scorpion toxin BmKKx2.
Cell Biosci,
2014
, 4 (18).
332
Nielsen JB
et al.
Gain-of-function mutations in potassium channel subunit KCNE2 associated with early-onset lone atrial fibrillation.
Biomark Med,
2014
, 8 (557-70).
333
Goodchild SJ
et al.
Gating charge movement precedes ionic current activation in hERG channels.
Channels (Austin),
2014
, 8 (84-9).
334
Liu J
et al.
Patch-clamp technique in ESC-derived cardiomyocytes.
Methods Mol. Biol.,
2014
, 1181 (203-14).
335
Guo X
et al.
Discovery of aroyl piperazine derivatives as IKr & IKs dual inhibitors for cardiac arrhythmia treatment.
Med Chem,
2014
, 10 (497-505).
336
Sanders NG
et al.
Antimalarial efficacy of hydroxyethylapoquinine (SN-119) and its derivatives.
Antimicrob. Agents Chemother.,
2014
, 58 (820-7).
337
Yu CC
et al.
Apamin does not inhibit human cardiac Na+ current, L-type Ca2+ current or other major K+ currents.
PLoS ONE,
2014
, 9 (e96691).
338
Tanaka H
et al.
Effect of terfenadine and pentamidine on the HERG channel and its intracellular trafficking: combined analysis with automated voltage clamp and confocal microscopy.
Biol. Pharm. Bull.,
2014
, 37 (1826-30).
339
Lin TF
et al.
The Eag domain regulates the voltage-dependent inactivation of rat Eag1 K+ channels.
PLoS ONE,
2014
, 9 (e110423).
340
Anderson CL
et al.
Large-scale mutational analysis of Kv11.1 reveals molecular insights into type 2 long QT syndrome.
Nat Commun,
2014
, 5 (5535).
341
Tong WC
et al.
Computational modeling reveals key contributions of KCNQ and hERG currents to the malleability of uterine action potentials underpinning labor.
PLoS ONE,
2014
, 9 (e114034).
342
Hancox JC
et al.
Modification of KCNH2-encoded cardiac potassium channels by KCNE1 polymorphism.
Circ. J.,
2014
, 78 (2330).
343
Schweigmann U
et al.
Elevated heart rate triggers action potential alternans and sudden death. translational study of a homozygous KCNH2 mutation.
PLoS ONE,
2014
, 9 (e103150).
344
Zhang K
et al.
Berberine induces hERG channel deficiency through trafficking inhibition.
Cell. Physiol. Biochem.,
2014
, 34 (691-702).
345
Lee SH
et al.
Blockade of HERG human K+ channels by the antidepressant drug paroxetine.
Biol. Pharm. Bull.,
2014
, 37 (1495-504).
346
Tabata T
et al.
Modification of KCNH2-encoded cardiac potassium channels by KCNE1 polymorphism.
Circ. J.,
2014
, 78 (2331).
347
Lu J
et al.
Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes.
PLoS ONE,
2014
, 9 (e115648).
348
Guo J
et al.
Structure driven design of novel human ether-a-go-go-related-gene channel (hERG1) activators.
PLoS ONE,
2014
, 9 (e105553).
349
Zeng H
et al.
Halide Ion Effects on Human Ether-à-go-go Related Gene Potassium Channel Properties.
Assay Drug Dev Technol,
2013 Nov-Dec
, 11 (544-50).
350
Beattie KA
et al.
Evaluation of an in silico cardiac safety assay: Using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge.
J Pharmacol Toxicol Methods,
2013 Jul-Aug
, 68 (88-96).
351
Morissette P
et al.
The anesthetized guinea pig: An effective early cardiovascular derisking and lead optimization model.
J Pharmacol Toxicol Methods,
2013 Jul-Aug
, 68 (137-49).
352
Elkins RC
et al.
Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment.
J Pharmacol Toxicol Methods,
2013 Jul-Aug
, 68 (112-22).
353
Himmel HM
Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: Effects of reference compounds.
J Pharmacol Toxicol Methods,
2013 Jul-Aug
, 68 (97-111).
354
Rampe D
et al.
A history of the role of the hERG channel in cardiac risk assessment.
J Pharmacol Toxicol Methods,
2013 Jul-Aug
, 68 (13-22).
355
Qu Y
et al.
Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay.
J Pharmacol Toxicol Methods,
2013 Jul-Aug
, 68 (74-81).
356
Chun YS
et al.
Cholesterol regulates HERG K+ channel activation by increasing phospholipase C β1 expression.
Channels (Austin),
2013 Jul-Aug
, 7 (275-87).
357
Gillie DJ
et al.
Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG.
J Pharmacol Toxicol Methods,
2013 Jan-Feb
, 67 (33-44).
358
Haugaa KH
et al.
Abnormal electroencephalograms in patients with long QT syndrome.
Heart Rhythm,
2013
Sep
27
, ().
360
Park MH
et al.
Effect of azelastine on cardiac repolarization of guinea-pig cardiomyocytes, hERG K⁺ channel, and human L-type and T-type Ca²⁺ channel.
J. Pharmacol. Sci.,
2013
Sep
20
, 123 (67-77).
361
Wang N
et al.
Procaine, a state-dependent blocker, inhibits HERG channels by helix residue Y652 and F656 in the S6 transmembrane domain.
J. Pharmacol. Sci.,
2013
Sep
20
, 123 (25-35).
362
Haitin Y
et al.
The structural mechanism of KCNH-channel regulation by the eag domain.
Nature,
2013
Sep
19
, 501 (444-8).
363
Diamant UB
et al.
Electrophysiological Phenotype in the LQTS Mutations Y111C and R518X in the KCNQ1 Gene.
J. Appl. Physiol.,
2013
Sep
19
, ().
364
Baczkó I
et al.
Characterization of a novel multi-functional resveratrol derivative for the treatment of atrial fibrillation.
Br. J. Pharmacol.,
2013
Sep
18
, ().
365
Di Veroli GY
et al.
hERG Inhibitors With Similar Potency But Different Binding Kinetics Do Not Pose the Same Proarrhythmic Risk: Implications for Drug Safety Assessment.
J. Cardiovasc. Electrophysiol.,
2013
Sep
12
, ().
366
Cordeiro JM
et al.
Developmental changes in expression and biophysics of ion channels in the canine ventricle.
J. Mol. Cell. Cardiol.,
2013
Sep
10
, 64C (79-89).
367
Hedley PL
et al.
The Role of CAV3 in Long QT Syndrome: Clinical and Functional Assessment of a Caveolin-3/Kv11.1 Double Heterozygote Versus Caveolin-3 Single Heterozygote.
Circ Cardiovasc Genet,
2013
Sep
10
, ().
368
Liu C
et al.
Postmortem molecular analysis of KCNQ1, KCNH2, KCNE1 and KCNE2 genes in sudden unexplained nocturnal death syndrome in the Chinese Han population.
Forensic Sci. Int.,
2013
Sep
10
, 231 (82-7).
369
Washburn DG
et al.
The discovery of potent blockers of the canonical transient receptor channels, TRPC3 and TRPC6, based on an anilino-thiazole pharmacophore.
Bioorg. Med. Chem. Lett.,
2013
Sep
1
, 23 (4979-84).
370
Park JK
et al.
Single Nucleotide Deletion Mutation of KCNH2 Gene is Responsible for LQT Syndrome in a 3-Generation Korean Family.
J. Korean Med. Sci.,
2013
Sep
, 28 (1388-93).
371
Cheng YM
et al.
Functional interactions of voltage sensor charges with an S2 hydrophobic plug in hERG channels.
J. Gen. Physiol.,
2013
Sep
, 142 (289-303).
372
Perry MD
et al.
Hydrophobic interactions between the voltage sensor and pore mediate inactivation in Kv11.1 channels.
J. Gen. Physiol.,
2013
Sep
, 142 (275-88).
373
Nawathe PA
et al.
An LQTS6 MiRP1 mutation suppresses pacemaker current and is associated with sinus bradycardia.
J. Cardiovasc. Electrophysiol.,
2013
Sep
, 24 (1021-7).
374
Zhang P
et al.
Blockade of the human ether-a-go-go-related gene potassium channel by ketamine.
J. Pharm. Pharmacol.,
2013
Sep
, 65 (1321-8).
375
Fischer F
et al.
Acute and subacute effects of the selective serotonin-noradrenaline reuptake inhibitor duloxetine on cardiac hERG channels.
Naunyn Schmiedebergs Arch. Pharmacol.,
2013
Sep
, 386 (795-804).
376
Olesen MS
et al.
Very early onset lone atrial fibrillation patients have a high prevalence of rare variants in genes previously associated with atrial fibrillation.
Heart Rhythm,
2013
Oct
18
, ().
377
Niculescu D
et al.
Erg potassium currents of neonatal mouse Purkinje cells exhibit fast gating kinetics and are inhibited by mGluR1 activation.
J. Neurosci.,
2013
Oct
16
, 33 (16729-40).
378
Meng J
et al.
Compound ICA-105574 prevents arrhythmias induced by cardiac delayed repolarization.
Eur. J. Pharmacol.,
2013
Oct
15
, 718 (87-97).
379
Hasegawa K
et al.
A Novel KCNQ1 Missense Mutation Identified in a Patient with Juvenile-Onset Atrial Fibrillation Causes Constitutively Open IKs Channels.
Heart Rhythm,
2013
Oct
1
, ().
380
Cuneo BF
et al.
Arrhythmia phenotype during fetal life suggests long-QT syndrome genotype: risk stratification of perinatal long-QT syndrome.
Circ Arrhythm Electrophysiol,
2013
Oct
, 6 (946-51).
381
Orts DJ
et al.
BcsTx3 is a founder of a novel sea anemone toxin family of potassium channel blocker.
FEBS J.,
2013
Oct
, 280 (4839-52).
382
Andreasen L
et al.
Genetic Modifier of the QTc Interval Associated With Early-Onset Atrial Fibrillation.
Can J Cardiol,
2013
Oct
, 29 (1234-40).
383
Yoshinaga M
et al.
Electrocardiographic screening of 1-month-old infants for identifying prolonged QT intervals.
Circ Arrhythm Electrophysiol,
2013
Oct
, 6 (932-8).
384
Gianulis EC
et al.
Direct interaction of eag domains and cyclic nucleotide-binding homology domains regulate deactivation gating in hERG channels.
J. Gen. Physiol.,
2013
Oct
, 142 (351-66).
385
Fiore A
et al.
Characterization of hERG1 channel role in mouse colorectal carcinogenesis.
Cancer Med,
2013
Oct
, 2 (583-94).
386
Salyer SA
et al.
Vacuolar ATPase driven potassium transport in highly metastatic breast cancer cells.
Biochim. Biophys. Acta,
2013
Oct
, 1832 (1734-43).
387
Lee YS
et al.
Long QT syndrome: a Korean single center study.
J. Korean Med. Sci.,
2013
Oct
, 28 (1454-60).
388
Bodi I
et al.
Differential effects of the β-adrenoceptor blockers carvedilol and metoprolol on SQT1- and SQT2-mutant channels.
J. Cardiovasc. Electrophysiol.,
2013
Oct
, 24 (1163-71).
389
Kamei S
et al.
Molecular analysis of potassium ion channel genes in sudden death cases among patients administered psychotropic drug therapy: are polymorphisms in LQT genes a potential risk factor?
J. Hum. Genet.,
2013
Nov
28
, ().
390
Nogawa H
et al.
Effects of probucol, a typical hERG expression inhibitor, on in vivo QT interval prolongation in conscious dogs.
Eur. J. Pharmacol.,
2013
Nov
15
, 720 (29-37).
391
Friddin MS
et al.
Single-channel electrophysiology of cell-free expressed ion channels by direct incorporation in lipid bilayers.
Analyst,
2013
Nov
12
, 138 (7294-8).
392
Stump MR
et al.
LQT2 nonsense mutations generate trafficking defective NH2-terminally truncated channels by the reinitiation of translation.
Am. J. Physiol. Heart Circ. Physiol.,
2013
Nov
1
, 305 (H1397-404).
393
Ayon RJ
et al.
Mutant hERG channel traffic jam. Focus on "Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum".
Am. J. Physiol., Cell Physiol.,
2013
Nov
1
, 305 (C916-8).
394
Smith JL
et al.
Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum.
Am. J. Physiol., Cell Physiol.,
2013
Nov
1
, 305 (C919-30).
395
Tang H
et al.
Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one.
Bioorg. Med. Chem. Lett.,
2013
Nov
1
, 23 (5829-32).
396
Coi A
et al.
Combining structure- and ligand-based approaches for studies of interactions between different conformations of the hERG K+ channel pore and known ligands.
J. Mol. Graph. Model.,
2013
Nov
, 46 (93-104).
397
Almilaji A
et al.
AMP-activated protein kinase regulates hERG potassium channel.
Pflugers Arch.,
2013
Nov
, 465 (1573-82).
398
Oshima A
et al.
Reconstitution of human ether-a-go-go-related gene channels in microfabricated silicon chips.
Anal. Chem.,
2013
May
7
, 85 (4363-9).
399
Lamothe SM
et al.
The serum- and glucocorticoid-inducible kinases SGK1 and SGK3 regulate hERG channel expression via ubiquitin ligase Nedd4-2 and GTPase Rab11.
J. Biol. Chem.,
2013
May
24
, 288 (15075-84).
400
Koenig X
et al.
Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: A study to assess the drug's cardiac ion channel profile.
Toxicol. Appl. Pharmacol.,
2013
May
22
, ().
401
Doherty KR
et al.
Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes.
Toxicol. Appl. Pharmacol.,
2013
May
21
, ().
402
Leanza L
et al.
Correlation between potassium channel expression and sensitivity to drug-induced cell death in tumor cell lines.
Curr. Pharm. Des.,
2013
May
16
, ().
403
Mitton-Fry MJ
et al.
Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
Bioorg. Med. Chem. Lett.,
2013
May
15
, 23 (2955-61).
404
Leifert A
et al.
Differential hERG ion channel activity of ultrasmall gold nanoparticles.
Proc. Natl. Acad. Sci. U.S.A.,
2013
May
14
, 110 (8004-9).
405
de la Peña P
et al.
Mapping of interactions between the N- and C-termini and the channel core in HERG K+ channels.
Biochem. J.,
2013
May
1
, 451 (463-74).
406
Andaloussi M
et al.
A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: comparison of hERG binding and target residence time with PF-3893787.
Bioorg. Med. Chem. Lett.,
2013
May
1
, 23 (2663-70).
407
Carr DB
et al.
Effects of injectable HPβCD-diclofenac on the human delayed rectifier potassium channel current in vitro and on proarrhythmic QTc in vivo.
Clin Ther,
2013
May
, 35 (646-58).
408
An HS
et al.
Sudden cardiac arrest during anesthesia in a 30-month-old boy with syndactyly: a case of genetically proven Timothy syndrome.
J. Korean Med. Sci.,
2013
May
, 28 (788-91).
409
McBride CM
et al.
Mechanistic basis for type 2 long QT syndrome caused by KCNH2 mutations that disrupt conserved arginine residues in the voltage sensor.
J. Membr. Biol.,
2013
May
, 246 (355-64).
410
Wei X
et al.
ZC88, a novel 4-amino piperidine analog, inhibits the growth of neuroblastoma cells through blocking hERG potassium channel.
Cancer Biol. Ther.,
2013
May
, 14 (450-7).
411
Aziz PF
et al.
Do LQTS gene single nucleotide polymorphisms alter QTc intervals at rest and during exercise stress testing?
Ann Noninvasive Electrocardiol,
2013
May
, 18 (288-93).
412
Matsa E
et al.
Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes.
Eur. Heart J.,
2013
Mar
6
, ().
413
Guo B
et al.
Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent.
J. Med. Chem.,
2013
Mar
28
, 56 (2642-50).
414
Park JE
et al.
Synthesis and biological evaluation of 1-(2-hydroxy-3-phenyloxypropyl)piperazine derivatives as T-type calcium channel blockers.
Bioorg. Med. Chem. Lett.,
2013
Mar
15
, 23 (1887-90).
415
Long Y
et al.
Mechanism of HERG potassium channel inhibition by tetra-n-octylammonium bromide and benzethonium chloride.
Toxicol. Appl. Pharmacol.,
2013
Mar
1
, 267 (155-66).
416
Babcock JJ
et al.
hERG channel function: beyond long QT.
Acta Pharmacol. Sin.,
2013
Mar
, 34 (329-35).
417
Hashimoto R
et al.
The KCNH2 gene is associated with neurocognition and the risk of schizophrenia.
World J. Biol. Psychiatry,
2013
Mar
, 14 (114-20).
418
Moorthy NS
et al.
QSAR and pharmacophore analysis of a series of piperidinyl urea derivatives as HERG blockers and H3 antagonists.
Curr Drug Discov Technol,
2013
Mar
, 10 (47-58).
419
Orts DJ
et al.
Biochemical and electrophysiological characterization of two sea anemone type 1 potassium toxins from a geographically distant population of Bunodosoma caissarum.
Mar Drugs,
2013
Mar
, 11 (655-79).
420
Jehle J
et al.
Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells.
Br. J. Pharmacol.,
2013
Mar
, 168 (1215-29).
421
Munoz C
et al.
Klotho sensitivity of the hERG channel.
FEBS Lett.,
2013
Jun
5
, 587 (1663-8).
422
Steinke K
et al.
Coxsackievirus B3 modulates cardiac ion channels.
FASEB J.,
2013
Jun
27
, ().
423
Colenso CK
et al.
Interactions between voltage sensor and pore domains in a hERG K+ channel model from molecular simulations and the effects of a voltage sensor mutation.
J Chem Inf Model,
2013
Jun
24
, 53 (1358-70).
424
Chen Y
et al.
Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics.
J. Med. Chem.,
2013
Jun
13
, 56 (4671-90).
425
Ginman T
et al.
Core refinement toward permeable β-secretase (BACE-1) inhibitors with low hERG activity.
J. Med. Chem.,
2013
Jun
13
, 56 (4181-205).
426
Byeon SR
et al.
Therapeutic and pharmacokinetic characterizations of an anti-amyloidogenic bis-styrylbenzene derivative for Alzheimer's disease treatment.
Bioorg. Med. Chem. Lett.,
2013
Jun
1
, 23 (3467-9).
427
Wang S
et al.
Recent developments in computational prediction of HERG blockage.
Curr Top Med Chem,
2013
Jun
1
, 13 (1317-26).
428
Santos Y
et al.
Arrhythmogenic effect of a crude extract from sea anemone Condylactis gigantea: possible involvement of rErg1 channels.
Toxicon,
2013
Jun
1
, 67 (47-54).
429
Townsend C
et al.
Predicting Drug-Induced QT Prolongation and Torsades de Pointes: A Review of Preclinical Endpoint Measures.
Curr Protoc Pharmacol,
2013
Jun
, Chapter 10 (Unit10.16).
430
Gravel AE
et al.
An NMR investigation of the structure, function and role of the hERG channel selectivity filter in the long QT syndrome.
Biochim. Biophys. Acta,
2013
Jun
, 1828 (1494-502).
431
Brudeli B
et al.
Synthesis and pharmacological properties of a new hydrophilic and orally bioavailable 5-HT4 antagonist.
Eur J Med Chem,
2013
Jun
, 64 (629-37).
432
Lin K
et al.
Allocryptopine and benzyltetrahydropalmatine block hERG potassium channels expressed in HEK293 cells.
Acta Pharmacol. Sin.,
2013
Jun
, 34 (847-58).
433
Stowasser M
Primary aldosteronism and potassium channel mutations.
Curr Opin Endocrinol Diabetes Obes,
2013
Jun
, 20 (170-9).
434
Lahtinen AM
et al.
Prevalence of arrhythmia-associated gene mutations and risk of sudden cardiac death in the Finnish population.
Ann. Med.,
2013
Jun
, 45 (328-35).
435
Kazmierczak M
et al.
External pH modulates EAG superfamily K+ channels through EAG-specific acidic residues in the voltage sensor.
J. Gen. Physiol.,
2013
Jun
, 141 (721-35).
436
Arcangeli A
et al.
High hERG1 expression in advanced melanoma.
Melanoma Res.,
2013
Jun
, 23 (185-90).
437
Brelidze TI
et al.
Structure of the C-terminal region of an ERG channel and functional implications.
Proc. Natl. Acad. Sci. U.S.A.,
2013
Jul
9
, 110 (11648-53).
438
Nilsson MF
et al.
Comparative effects of sodium channel blockers in short term rat whole embryo culture.
Toxicol. Appl. Pharmacol.,
2013
Jul
8
, ().
439
Cui Z
et al.
Regulation of the human ether-a-go-go-related gene (hERG) channel by Rab4 protein through neural precursor cell-expressed developmentally down-regulated protein 4-2 (Nedd4-2).
J. Biol. Chem.,
2013
Jul
26
, 288 (21876-86).
440
Kiss T
et al.
Identification of diterpene alkaloids from Aconitum napellus subsp. firmum and GIRK channel activities of some Aconitum alkaloids.
Fitoterapia,
2013
Jul
19
, ().
441
Duchatelet S
et al.
Identification of a KCNQ1 Polymorphism Acting as a Protective Modifier against Arrhythmic Risk in Long QT Syndrome.
Circ Cardiovasc Genet,
2013
Jul
15
, ().
442
Seki M
et al.
Synthesis and biological evaluation of pyrrolidine derivatives as novel and potent sodium channel blockers for the treatment of ischemic stroke.
Bioorg. Med. Chem. Lett.,
2013
Jul
15
, 23 (4230-4).
443
Ryu S
et al.
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
Bioorg. Med. Chem. Lett.,
2013
Jul
1
, 23 (3848-51).
444
Takanari H
et al.
Efficient and specific cardiac IK1 inhibition by a new pentamidine analogue.
Cardiovasc. Res.,
2013
Jul
1
, 99 (203-14).
445
Varkevisser R
et al.
Structure-activity relationships of pentamidine-affected ion channel trafficking and dofetilide mediated rescue.
Br. J. Pharmacol.,
2013
Jul
, 169 (1322-34).
446
Son MK
et al.
Genetic mutation in korean patients of sudden cardiac arrest as a surrogating marker of idiopathic ventricular arrhythmia.
J. Korean Med. Sci.,
2013
Jul
, 28 (1021-6).
447
Lieve KV
et al.
Results of genetic testing in 855 consecutive unrelated patients referred for long QT syndrome in a clinical laboratory.
Genet Test Mol Biomarkers,
2013
Jul
, 17 (553-61).
448
Rayan A
et al.
Indexing molecules for their hERG liability.
Eur J Med Chem,
2013
Jul
, 65 (304-14).
449
Jou CJ
et al.
An In Vivo Cardiac Assay to Determine the Functional Consequences of Putative Long QT Syndrome Mutations.
Circ. Res.,
2013
Jan
9
, ().
450
Ford J
et al.
Human Electrophysiological and Pharmacological Properties of XEN-D0101: A Novel Atrial Selective Kv1.5/IKur Inhibitor.
J. Cardiovasc. Pharmacol.,
2013
Jan
29
, ().
451
Di Martino GP
et al.
An automated docking protocol for hERG channel blockers.
J Chem Inf Model,
2013
Jan
28
, 53 (159-75).
452
Li H
et al.
The discovery of fused oxadiazepines as gamma secretase modulators for treatment of Alzheimer's disease.
Bioorg. Med. Chem. Lett.,
2013
Jan
15
, 23 (466-71).
453
Di Veroli GY
et al.
High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.
Am. J. Physiol. Heart Circ. Physiol.,
2013
Jan
1
, 304 (H104-17).
454
Zhang Y
et al.
Arsenic trioxide-induced hERG K(+) channel deficiency can be rescued by matrine and oxymatrine through up-regulating transcription factor Sp1 expression.
Biochem. Pharmacol.,
2013
Jan
1
, 85 (59-68).
455
Narayana Moorthy NS
et al.
Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design.
Curr Drug Targets,
2013
Jan
1
, 14 (102-13).
456
Liu L
et al.
A novel mutation in the transmembrane nonpore region of the KCNH2 gene causes severe clinical manifestations of long QT syndrome.
Heart Rhythm,
2013
Jan
, 10 (61-7).
457
Zarzoso M
et al.
Mission possible: RNA interference rescues the hERG current.
Heart Rhythm,
2013
Jan
, 10 (137-8).
458
Beattie DT
et al.
An in vitro investigation of the cardiovascular effects of the 5-HT(4) receptor selective agonists, velusetrag and TD-8954.
Vascul. Pharmacol.,
2013
Jan
, 58 (150-6).
459
Lu X
et al.
RNA interference targeting E637K mutation rescues hERG channel currents and restores its kinetic properties.
Heart Rhythm,
2013
Jan
, 10 (128-36).
460
Braam SR
et al.
Repolarization reserve determines drug responses in human pluripotent stem cell derived cardiomyocytes.
Stem Cell Res,
2013
Jan
, 10 (48-56).
461
Ng CA
et al.
Insights into hERG K+ channel structure and function from NMR studies.
Eur. Biophys. J.,
2013
Jan
, 42 (71-9).
462
Wei T
et al.
[Effect of berberine, liensinine and neferine on HERG channel expression].
Zhongguo Zhong Yao Za Zhi,
2013
Jan
, 38 (239-44).
463
Zhang A
et al.
L539 fs/47, a truncated mutation of human ether-a-go-go-related gene (hERG), decreases hERG ion channel currents in HEK 293 cells.
Clin. Exp. Pharmacol. Physiol.,
2013
Jan
, 40 (28-36).
464
Sirenko O
et al.
Multiparameter In Vitro Assessment of Compound Effects on Cardiomyocyte Physiology Using iPSC Cells.
J Biomol Screen,
2013
Jan
, 18 (39-53).
465
Terrenoire C
et al.
Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics.
J. Gen. Physiol.,
2013
Jan
, 141 (61-72).
466
Su X
et al.
Effect of microculture on cell metabolism and biochemistry: do cells get stressed in microchannels?
Anal. Chem.,
2013
Feb
5
, 85 (1562-70).
467
Hong HK
et al.
Block of hERG K+ channel and prolongation of action potential duration by fluphenazine at submicromolar concentration.
Eur. J. Pharmacol.,
2013
Feb
28
, 702 (165-73).
468
Andreasen C
et al.
Mutations in Genes Encoding Cardiac Ion Channels Previously Associated With Sudden Infant Death Syndrome (SIDS) Are Present With High Frequency in New Exome Data.
Can J Cardiol,
2013
Feb
25
, ().
469
Hausammann GJ
et al.
Generation of an antibody toolbox to characterize hERG.
Biochem. Biophys. Res. Commun.,
2013
Feb
1
, 431 (70-5).
470
Harris RA
et al.
Human metastable epiallele candidates link to common disorders.
Epigenetics,
2013
Feb
, 8 (157-63).
471
Yang LJ
et al.
New targets for the antitumor activity of gambogic acid in hematologic malignancies.
Acta Pharmacol. Sin.,
2013
Feb
, 34 (191-8).
472
Gustina AS
et al.
The eag domain regulates hERG channel inactivation gating via a direct interaction.
J. Gen. Physiol.,
2013
Feb
, 141 (229-41).
473
Dong H
et al.
Functional expression of ERG1 potassium channels in rat alveolar macrophages.
J. Mol. Histol.,
2013
Feb
, 44 (117-24).
474
Norring SA
et al.
Channel sialic acids limit hERG channel activity during the ventricular action potential.
FASEB J.,
2013
Feb
, 27 (622-31).
475
Silva D
et al.
Novel mutation in the KCNH2 gene associated with long QT syndrome.
Rev Port Cardiol,
2013
Feb
, 32 (163-4).
476
Zemzemi N
et al.
Computational assessment of drug-induced effects on the electrocardiogram: from ion channel to body surface potentials.
Br. J. Pharmacol.,
2013
Feb
, 168 (718-33).
477
Hausammann GJ
et al.
Chimeric hERG channels containing a tetramerization domain are functional and stable.
Biochemistry,
2013
Dec
23
, 52 (9237-45).
478
Shi YP
et al.
External protons destabilize the activated voltage sensor in hERG channels.
Eur. Biophys. J.,
2013
Dec
21
, ().
479
Louvel J
et al.
Removal of human ether-à-go-go related gene (hERG) K+ channel affinity through rigidity: a case of clofilium analogues.
J. Med. Chem.,
2013
Dec
12
, 56 (9427-40).
480
Bellin M
et al.
Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome.
EMBO J.,
2013
Dec
11
, 32 (3161-75).
481
Iwai C
et al.
Hsp90 prevents interaction between CHIP and HERG proteins to facilitate maturation of wild-type and mutant HERG proteins.
Cardiovasc. Res.,
2013
Dec
1
, 100 (520-8).
482
He YL
et al.
High-quality triplicate electrocardiogram monitoring in a first-in-man study: potential for early detection of drug-induced QT prolongation.
Int J Clin Pharmacol Ther,
2013
Dec
, 51 (948-57).
483
Apaja PM
et al.
Ubiquitination-dependent quality control of hERG K+ channel with acquired and inherited conformational defect at the plasma membrane.
Mol. Biol. Cell,
2013
Dec
, 24 (3787-804).
484
Hintsa T
et al.
Work stress and the long QT syndrome: high job strain and effort-reward imbalance at work associated with arrhythmic risk in the long QT syndrome.
J. Occup. Environ. Med.,
2013
Dec
, 55 (1387-93).
485
Goineau S
et al.
In vitro safety cardiovascular pharmacology studies: impact of formulation preparation and analysis.
Regul. Toxicol. Pharmacol.,
2013
Dec
, 67 (499-505).
486
Lin J
et al.
[Protein tyrosine phosphatase non-receptor type 12 negatively regulates cardiac HERG channel currents].
Nan Fang Yi Ke Da Xue Xue Bao,
2013
Dec
, 33 (1718-22).
487
Fortunato A
et al.
An analytical method for the quantification of hERG1 channel gene expression in human colorectal cancer.
Diagn. Mol. Pathol.,
2013
Dec
, 22 (215-21).
488
Dowling JE
et al.
Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo.
ACS Med Chem Lett,
2013
Aug
8
, 4 (800-5).
489
Kato K
et al.
Cardiac Channelopathies Associated with Infantile Fatal Ventricular Arrhythmias: From the Cradle to the Bench.
J. Cardiovasc. Electrophysiol.,
2013
Aug
26
, ().
490
Hayashi M
et al.
Molecular basis of potassium channels in pancreatic duct epithelial cells.
Channels (Austin),
2013
Aug
20
, 7 ().
491
Dou Y
et al.
The neutral, hydrophobic isoleucine at position I521 in the extracellular S4 domain of hERG contributes to channel gating equilibrium.
Am. J. Physiol., Cell Physiol.,
2013
Aug
15
, 305 (C468-78).
492
K E Y
et al.
Trafficking defects in PAS domain mutant Kv11.1 channels: roles of reduced domain stability and altered domain-domain interactions.
Biochem. J.,
2013
Aug
15
, 454 (69-77).
493
Sun H
et al.
Are hERG channel blockers also phospholipidosis inducers?
Bioorg. Med. Chem. Lett.,
2013
Aug
15
, 23 (4587-90).
494
Cicek MS
et al.
Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel.
Hum. Mol. Genet.,
2013
Aug
1
, 22 (3038-47).
495
Kruse M
et al.
The phosphoinositide sensitivity of the KV channel family.
Channels (Austin),
2013
Aug
1
, 7 ().
496
Partemi S
et al.
Loss-of-function KCNH2 mutation in a family with long QT syndrome, epilepsy, and sudden death.
Epilepsia,
2013
Aug
, 54 (e112-6).
497
Sroubek J
et al.
Sequence and structure-specific elements of HERG mRNA determine channel synthesis and trafficking efficiency.
FASEB J.,
2013
Aug
, 27 (3039-53).
498
Gao Y
et al.
A novel deletion-frameshift mutation in the S1 region of HERG gene in a Chinese family with long QT syndrome.
Chin. Med. J.,
2013
Aug
, 126 (3093-6).
499
Choi SW
et al.
Class 3 inhibition of hERG K+ channel by caffeic acid phenethyl ester (CAPE) and curcumin.
Pflugers Arch.,
2013
Aug
, 465 (1121-34).
500
Harris K
et al.
Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays.
Toxicol. Sci.,
2013
Aug
, 134 (412-26).
501
Arslan Yildiz A
et al.
Biomimetic membrane platform containing hERG potassium channel and its application to drug screening.
Analyst,
2013
Apr
7
, 138 (2007-12).
502
Perry MD
et al.
Pore helices play a dynamic role as integrators of domain motion during Kv11.1 channel inactivation gating.
J. Biol. Chem.,
2013
Apr
19
, 288 (11482-91).
503
Carvalho JF
et al.
Strategies to reduce HERG K+ channel blockade. Exploring heteroaromaticity and rigidity in novel pyridine analogues of dofetilide.
J. Med. Chem.,
2013
Apr
11
, 56 (2828-40).
504
Crotti L
et al.
Long QT syndrome-associated mutations in intrauterine fetal death.
JAMA,
2013
Apr
10
, 309 (1473-82).
505
Wang Z
et al.
Components of gating charge movement and S4 voltage-sensor exposure during activation of hERG channels.
J. Gen. Physiol.,
2013
Apr
, 141 (431-43).
506
Shinwari ZM
et al.
Identification of a novel KCNQ1 mutation in a large Saudi family with long QT syndrome: clinical consequences and preventive implications.
Clin. Genet.,
2013
Apr
, 83 (370-4).
508
Yoshikane Y
et al.
A case of long QT syndrome with triple gene abnormalities: digenic mutations in KCNH2 and SCN5A and gene variant in KCNE1.
Heart Rhythm,
2013
Apr
, 10 (600-3).
509
He FZ
et al.
Current pharmacogenomic studies on hERG potassium channels.
Trends Mol Med,
2013
Apr
, 19 (227-38).
510
Adaixo R
et al.
Structural properties of PAS domains from the KCNH potassium channels.
PLoS ONE,
2013
, 8 (e59265).
511
Abdelhady S
et al.
Erg channel is critical in controlling cell volume during cell cycle in embryonic stem cells.
PLoS ONE,
2013
, 8 (e72409).
512
Moric-Janiszewska E
et al.
Quantitative PCR as an Alternative in the Diagnosis of Long-QT Syndrome.
Biomed Res Int,
2013
, 2013 (418604).
513
Ouadid-Ahidouch H
et al.
K(+) channels and cell cycle progression in tumor cells.
Front Physiol,
2013
, 4 (220).
514
Shimizu W
Update of diagnosis and management of inherited cardiac arrhythmias.
Circ. J.,
2013
, 77 (2867-72).
515
Ng CA
et al.
C-Terminal β9-Strand of the Cyclic Nucleotide-Binding Homology Domain Stabilizes Activated States of Kv11.1 Channels.
PLoS ONE,
2013
, 8 (e77032).
516
Springer C
et al.
A fingerprint pair analysis of hERG inhibition data.
Chem Cent J,
2013
, 7 (167).
517
He F
et al.
The KCNH2 genetic polymorphism (1956, C>T) is a novel biomarker that is associated with CCB and α,β-ADR blocker response in EH patients in China.
PLoS ONE,
2013
, 8 (e61317).
518
Asayama M
et al.
Effects of an hERG activator, ICA-105574, on electrophysiological properties of canine hearts.
J. Pharmacol. Sci.,
2013
, 121 (1-8).
519
Kramer J
et al.
MICE Models: Superior to the HERG Model in Predicting Torsade de Pointes.
Sci Rep,
2013
, 3 (2100).
520
Kireeva N
et al.
Towards in silico identification of the human ether-a-go-go-related gene channel blockers: discriminative vs. generative classification models.
SAR QSAR Environ Res,
2013
, 24 (103-17).
521
Sampson HM
et al.
Compounds that correct F508del-CFTR trafficking can also correct other protein trafficking diseases: an in vitro study using cell lines.
Orphanet J Rare Dis,
2013
, 8 (11).
522
Zhao X
et al.
Ginkgo biloba extract and ginkgolide antiarrhythmic potential by targeting hERG and ICa-L channel.
J. Pharmacol. Sci.,
2013
, 123 (318-27).
523
Bethge N
et al.
Identification of highly methylated genes across various types of B-cell non-hodgkin lymphoma.
PLoS ONE,
2013
, 8 (e79602).
524
Mehnert JM
et al.
Electrophysiological characterization of spontaneously contracting cell aggregates obtained from rainbow trout larvae with multielectrode arrays.
Cell. Physiol. Biochem.,
2013
, 32 (1374-85).
525
Shu L
et al.
Modulation of HERG K+ channels by chronic exposure to activators and inhibitors of PKA and PKC: actions independent of PKA and PKC phosphorylation.
Cell. Physiol. Biochem.,
2013
, 32 (1830-44).
526
Karnik R
et al.
Endocytosis of HERG is clathrin-independent and involves arf6.
PLoS ONE,
2013
, 8 (e85630).
527
Pérez Riera AR
et al.
Congenital short QT syndrome: landmarks of the newest arrhythmogenic cardiac channelopathy.
Cardiol J,
2013
, 20 (464-71).
528
Okata S
et al.
The generation of induced pluripotent stem cells from a patient with KCNH2 G603D, without LQT2 disease associated symptom.
J. Med. Dent. Sci.,
2013
, 60 (17-22).
529
Ranjan AP
et al.
Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation.
J Nanobiotechnology,
2013
, 11 (40).
530
531
Thai KM
et al.
Pharmacophore modeling for antitargets.
Curr Top Med Chem,
2013
, 13 (1002-14).
532
Trolle C
et al.
Long QT interval in Turner syndrome--a high prevalence of LQTS gene mutations.
PLoS ONE,
2013
, 8 (e69614).
533
Babcock JJ
et al.
Integrated analysis of drug-induced gene expression profiles predicts novel hERG inhibitors.
PLoS ONE,
2013
, 8 (e69513).
534
Pakladok T
et al.
PIKfyve sensitivity of hERG channels.
Cell. Physiol. Biochem.,
2013
, 31 (785-94).
535
Lansu K
et al.
Potassium channel activation inhibits proliferation of breast cancer cells by activating a senescence program.
Cell Death Dis,
2013
, 4 (e652).
536
Crociani O
et al.
hERG1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer.
Sci Rep,
2013
, 3 (3308).
537
Mi Y
et al.
The role of potassium channel activation in celecoxib-induced analgesic action.
PLoS ONE,
2013
, 8 (e54797).
538
Andrsova I
et al.
Clinical characteristics of 30 Czech families with long QT syndrome and KCNQ1 and KCNH2 gene mutations: importance of exercise testing.
J Electrocardiol,
2012 Nov-Dec
, 45 (746-51).
539
Ildarova R
et al.
Sodium-channel blockers might contribute to the prevention of ventricular tachycardia in patients with long QT syndrome type 2: a description of 4 cases.
J Electrocardiol,
2012 May-Jun
, 45 (237-43).
540
[Three-dimensional structure of human Kv10.2 ion channel studied by single particle electron microscopy and molecular modeling].
Bioorg. Khim.,
2012 Mar-Apr
, 38 (177-84).
541
Zhao Y
et al.
Transfection by eukaryotic expression vector pcDNA3-HERG inhibits the cultured neonatal rabbit ventricular myocyte hypertrophy induced by phenylephrine.
Cardiovasc. Pathol.,
2012 Jul-Aug
, 21 (339-45).
542
Liu Q
et al.
Effect of daurisoline on HERG channel electrophysiological function and protein expression.
J. Nat. Prod.,
2012
Sep
28
, 75 (1539-45).
543
Guo J
et al.
Cell surface expression of human ether-a-go-go-related gene (hERG) channels is regulated by caveolin-3 protein via the ubiquitin ligase Nedd4-2.
J. Biol. Chem.,
2012
Sep
28
, 287 (33132-41).
544
Jindal HK
et al.
Proteomic analyses of transgenic LQT1 and LQT2 rabbit hearts elucidate an increase in expression and activity of energy producing enzymes.
J Proteomics,
2012
Sep
18
, 75 (5254-65).
545
Mattmann ME
et al.
Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator.
Bioorg. Med. Chem. Lett.,
2012
Sep
15
, 22 (5936-41).
546
Dossetter AG
et al.
Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.
Bioorg. Med. Chem. Lett.,
2012
Sep
1
, 22 (5563-8).
547
Tan PS
et al.
Voltage-sensing domain mode shift is coupled to the activation gate by the N-terminal tail of hERG channels.
J. Gen. Physiol.,
2012
Sep
, 140 (293-306).
548
Zumhagen S
et al.
Inherited long QT syndrome: clinical manifestation, genetic diagnostics, and therapy.
Herzschrittmacherther Elektrophysiol,
2012
Sep
, 23 (211-9).
549
Garg V
et al.
Tuning of EAG K(+) channel inactivation: molecular determinants of amplification by mutations and a small molecule.
J. Gen. Physiol.,
2012
Sep
, 140 (307-24).
550
Annedi SC
et al.
Discovery of a potent, orally bioavailable and highly selective human neuronal nitric oxide synthase (nNOS) inhibitor, N-(1-(piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide as a pre-clinical development candidate for the treatment of migraine.
Eur J Med Chem,
2012
Sep
, 55 (94-107).
551
Kapoor A
et al.
Human cytomegalovirus inhibition by cardiac glycosides: evidence for involvement of the HERG gene.
Antimicrob. Agents Chemother.,
2012
Sep
, 56 (4891-9).
552
Jonsson MK
et al.
Deciphering hERG channels: molecular basis of the rapid component of the delayed rectifier potassium current.
J. Mol. Cell. Cardiol.,
2012
Sep
, 53 (369-74).
553
Bhattarai D
et al.
Synthesis and in vitro antibacterial activity of novel 3-azabicyclo[3.3.0]octanyl oxazolidinones.
Chem Biol Drug Des,
2012
Sep
, 80 (388-97).
554
Lee SH
et al.
Blockade of human HERG K⁺ channels by rosiglitazone, an antidiabetic drug.
Arch. Pharm. Res.,
2012
Sep
, 35 (1655-64).
555
Quail T
et al.
Chaotic dynamics in cardiac aggregates induced by potassium channel block.
Chaos,
2012
Sep
, 22 (033140).
556
Cid JM
et al.
Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor.
J. Med. Chem.,
2012
Oct
25
, 55 (8770-89).
557
Durdagi S
et al.
Modeling of open, closed, and open-inactivated states of the hERG1 channel: structural mechanisms of the state-dependent drug binding.
J Chem Inf Model,
2012
Oct
22
, 52 (2760-74).
558
Abderemane-Ali F
et al.
Dual effect of phosphatidyl (4,5)-bisphosphate PIP2 on Shaker K+ channels.
J. Biol. Chem.,
2012
Oct
19
, 287 (36158-67).
559
Procopiou PA
et al.
Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.
Bioorg. Med. Chem.,
2012
Oct
15
, 20 (6097-108).
560
Giudicessi JR
et al.
Phylogenetic and physicochemical analyses enhance the classification of rare nonsynonymous single nucleotide variants in type 1 and 2 long-QT syndrome.
Circ Cardiovasc Genet,
2012
Oct
1
, 5 (519-28).
561
Chu W
et al.
Arsenic-induced interstitial myocardial fibrosis reveals a new insight into drug-induced long QT syndrome.
Cardiovasc. Res.,
2012
Oct
1
, 96 (90-8).
562
Högberg T
et al.
Melanin concentrating hormone receptor 1 (MCHR1) antagonists-Still a viable approach for obesity treatment?
Bioorg. Med. Chem. Lett.,
2012
Oct
1
, 22 (6039-47).
563
Khalaf AI
et al.
Design, synthesis and antibacterial activity of minor groove binders: the role of non-cationic tail groups.
Eur J Med Chem,
2012
Oct
, 56 (39-47).
564
Asghar MY
et al.
Sphingosine 1-phosphate and human ether-a'-go-go-related gene potassium channels modulate migration in human anaplastic thyroid cancer cells.
Endocr. Relat. Cancer,
2012
Oct
, 19 (667-80).
565
Lee HA
et al.
Wide spectrum of inhibitory effects of sertraline on cardiac ion channels.
Korean J. Physiol. Pharmacol.,
2012
Oct
, 16 (327-32).
566
Winkel BG
et al.
The prevalence of mutations in KCNQ1, KCNH2, and SCN5A in an unselected national cohort of young sudden unexplained death cases.
J. Cardiovasc. Electrophysiol.,
2012
Oct
, 23 (1092-8).
567
Wiśniowska B
et al.
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
J Appl Toxicol,
2012
Oct
, 32 (858-66).
568
Wen D
et al.
Validation of visualized transgenic zebrafish as a high throughput model to assay bradycardia related cardio toxicity risk candidates.
J Appl Toxicol,
2012
Oct
, 32 (834-42).
569
Zhao QH
et al.
[KCNQ1, KCNH2, KCNE1 and KCNE2 potassium channels gene variants in sudden manhood death syndrome].
Fa Yi Xue Za Zhi,
2012
Oct
, 28 (337-41, 346).
570
Nirogi R
et al.
Design, synthesis, and pharmacological evaluation of piperidin-4-yl amino aryl sulfonamides: novel, potent, selective, orally active, and brain penetrant 5-HT₆ receptor antagonists.
J. Med. Chem.,
2012
Nov
8
, 55 (9255-69).
571
Swahn BM
et al.
Design and synthesis of β-Site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
J. Med. Chem.,
2012
Nov
8
, 55 (9346-61).
572
Dong Q
et al.
Blocking of the human ether-à-go-go-related gene channel by imatinib mesylate.
Biol. Pharm. Bull.,
2012
Nov
30
, ().
573
Sherhod R
et al.
Automating knowledge discovery for toxicity prediction using jumping emerging pattern mining.
J Chem Inf Model,
2012
Nov
26
, 52 (3074-87).
574
Portonovo SA
et al.
hERG drug response measured in droplet bilayers.
Biomed Microdevices,
2012
Nov
18
, ().
575
Potet F
et al.
Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias.
J. Biol. Chem.,
2012
Nov
16
, 287 (39613-25).
576
Bahl A
et al.
The discovery of CCR3/H1 dual antagonists with reduced hERG risk.
Bioorg. Med. Chem. Lett.,
2012
Nov
1
, 22 (6688-93).
577
Edelmann J
et al.
Long QT syndrome mutation detection by SNaPshot technique.
Int. J. Legal Med.,
2012
Nov
, 126 (969-73).
578
Kinoshita K
et al.
A novel missense mutation causing a G487R substitution in the S2-S3 loop of human ether-à-go-go-related gene channel.
J. Cardiovasc. Electrophysiol.,
2012
Nov
, 23 (1246-53).
579
Stump MR
et al.
Early LQT2 nonsense mutation generates N-terminally truncated hERG channels with altered gating properties by the reinitiation of translation.
J. Mol. Cell. Cardiol.,
2012
Nov
, 53 (725-33).
580
Kam YL
et al.
HYP-1, a novel diamide compound, relieves inflammatory and neuropathic pain in rats.
Pharmacol. Biochem. Behav.,
2012
Nov
, 103 (33-42).
581
Zhang Y
et al.
hERG ion channel pharmacology: cell membrane liposomes in porous-supported lipid bilayers compared with whole-cell patch-clamping.
Eur. Biophys. J.,
2012
Nov
, 41 (949-58).
582
Xie S
et al.
Identification of a new specific Kv1.3 channel blocker, Ctri9577, from the scorpion Chaerilus tricostatus.
,
2012
May
8
, ().
583
Donovan AJ
et al.
LQT2 Mutation on the Kv11.1 Ion Channel Inhibits Current Activity by Ablating a PKCα Consensus Site.
,
2012
May
31
, ().
584
Du YM
et al.
18β-Glycyrrhetinic acid preferentially blocks late Na current generated by ΔKPQ Nav1.5 channels.
,
2012
May
21
, ().
585
Skidmore J
et al.
Identification of a series of 1,3,4-oxadiazol-2-amines as potent alpha-7 agonists with efficacy in the novel object recognition model of cognition.
Bioorg. Med. Chem. Lett.,
2012
May
15
, 22 (3560-3).
586
Kasai S
et al.
Synthesis, structure-activity relationship, and pharmacological studies of novel melanin-concentrating hormone receptor 1 antagonists 3-aminomethylquinolines: reducing human ether-a-go-go-related gene (hERG) associated liabilities.
J. Med. Chem.,
2012
May
10
, 55 (4336-51).
587
Tang H
et al.
Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism Diuretics.
ACS Med Chem Lett,
2012
May
10
, 3 (367-72).
588
Chen J
et al.
Binding interface of cardiac potassium channel proteins identified by hydrogen deuterium exchange of synthetic peptides.
Anal Bioanal Chem,
2012
May
, 403 (1303-9).
589
Jiménez-Vargas JM
et al.
Interacting sites of scorpion toxin ErgTx1 with hERG1 K+ channels.
Toxicon,
2012
May
, 59 (633-41).
590
Boström J
et al.
Oxadiazoles in medicinal chemistry.
J. Med. Chem.,
2012
Mar
8
, 55 (1817-30).
591
Skerlj R
et al.
Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication.
ACS Med Chem Lett,
2012
Mar
8
, 3 (216-21).
592
Wacker SJ
et al.
Identification of Selective Inhibitors of the Potassium Channel Kv1.1-1.2((3)) by High-Throughput Virtual Screening and Automated Patch Clamp.
,
2012
Mar
30
, ().
593
Menéndez ST
et al.
Role of HERG1 potassium channel in both malignant transformation and disease progression in head and neck carcinomas.
,
2012
Mar
30
, ().
594
Ramnauth J
et al.
1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors: lead optimization studies resulting in the identification of N-(1-(2-(methylamino)ethyl)-1,2,3,4-tetrahydroquinolin-6-yl)thiophene-2-carboximidamide as a p
J. Med. Chem.,
2012
Mar
22
, 55 (2882-93).
595
Hanrahan P
et al.
Substituted azaquinazolinones as modulators of GHSr-1a for the treatment of type II diabetes and obesity.
Bioorg. Med. Chem. Lett.,
2012
Mar
15
, 22 (2271-8).
596
Liu GX
et al.
Differential conditions for early after-depolarizations and triggered activity in cardiomyocytes derived from transgenic LQT1 and LQT2 rabbits.
J. Physiol. (Lond.),
2012
Mar
1
, 590 (1171-80).
597
Bregman H
et al.
The discovery of aminopyrazines as novel, potent Na(v)1.7 antagonists: hit-to-lead identification and SAR.
Bioorg. Med. Chem. Lett.,
2012
Mar
1
, 22 (2033-42).
598
Chakka N
et al.
Discovery and hit-to-lead optimization of pyrrolopyrimidines as potent, state-dependent Na(v)1.7 antagonists.
Bioorg. Med. Chem. Lett.,
2012
Mar
1
, 22 (2052-62).
599
Lacombe P
et al.
3,4-Diarylpiperidines as potent renin inhibitors.
Bioorg. Med. Chem. Lett.,
2012
Mar
1
, 22 (1953-7).
600
Moorthy NS
et al.
Structural analysis of 2-piperidin-4-yl-actamide derivatives for hERG blocking and MCH R1 antagonistic activities.
Curr Drug Discov Technol,
2012
Mar
, 9 (25-38).
601
Zhao XY
et al.
Frequency- and state-dependent blockade of human ether-a-go-go-related gene K+ channel by arecoline hydrobromide.
Chin. Med. J.,
2012
Mar
, 125 (1068-75).
602
Kaddar N
et al.
Tizanidine (Zanaflex): a muscle relaxant that may prolong the QT interval by blocking IKr.
J. Cardiovasc. Pharmacol. Ther.,
2012
Mar
, 17 (102-9).
603
Tan Y
et al.
Predicting the potency of hERG K⁺ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models.
J Mol Model,
2012
Mar
, 18 (1023-36).
604
Peterson LB
et al.
The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking.
Mol. Pharm.,
2012
Jun
4
, 9 (1841-6).
605
Gunnström M
et al.
Antipsychotic drugs cause bradycardia in GD 13 rat embryos in vitro.
,
2012
Jun
28
, ().
606
Su BH
et al.
Predictive toxicology modeling: protocols for exploring hERG classification and Tetrahymena pyriformis end point predictions.
J Chem Inf Model,
2012
Jun
25
, 52 (1660-73).
607
Pérez-Victoria I
et al.
Isolation and structural elucidation of cyclic tetrapeptides from Onychocola sclerotica.
J. Nat. Prod.,
2012
Jun
22
, 75 (1210-4).
608
Carosati E
et al.
1,4-Dihydropyridine Scaffold in Medicinal Chemistry, The Story so Far And Perspectives (Part 2): Action in Other Targets and Antitargets.
,
2012
Jun
18
, ().
609
Cumming JG
et al.
The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity.
Bioorg. Med. Chem. Lett.,
2012
Jun
15
, 22 (3895-9).
610
Pajouhesh H
et al.
Structure-activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors.
Bioorg. Med. Chem. Lett.,
2012
Jun
15
, 22 (4153-8).
611
Mihalic JT
et al.
Discovery of a novel melanin concentrating hormone receptor 1 (MCHR1) antagonist with reduced hERG inhibition.
Bioorg. Med. Chem. Lett.,
2012
Jun
1
, 22 (3781-5).
612
Zhao J
et al.
Inhibitory effects of a bisbenzylisoquinline alkaloid dauricine on HERG potassium channels.
J Ethnopharmacol,
2012
Jun
1
, 141 (685-91).
613
Guo J
et al.
A422T mutation in HERG potassium channel retained in ER is rescurable by pharmacologic or molecular chaperones.
Biochem. Biophys. Res. Commun.,
2012
Jun
1
, 422 (305-10).
614
Van Slyke AC
et al.
Proton block of the pore underlies the inhibition of hERG cardiac K+ channels during acidosis.
Am. J. Physiol., Cell Physiol.,
2012
Jun
, 302 (C1797-806).
615
Goineau S
et al.
Whole-cell configuration of the patch-clamp technique in the hERG channel assay to predict the ability of a compound to prolong QT interval.
Curr Protoc Pharmacol,
2012
Jun
, Chapter 10 (Unit 10.15.).
616
Lu HR
et al.
Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
Br. J. Pharmacol.,
2012
Jun
, 166 (1490-502).
617
Li P
et al.
Comparison of the effects of DC031050, a class III antiarrhythmic agent, on hERG channel and three neuronal potassium channels.
Acta Pharmacol. Sin.,
2012
Jun
, 33 (728-36).
618
Donner BC
et al.
A presumably benign human ether-a-go-go-related gene mutation (R176W) with a malignant primary manifestation of long QT syndrome.
Cardiol Young,
2012
Jun
, 22 (360-3).
619
Tester DJ
et al.
Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing.
Mayo Clin. Proc.,
2012
Jun
, 87 (524-39).
620
Gönczi M
et al.
Age-dependent changes in ion channel mRNA expression in canine cardiac tissues.
Gen. Physiol. Biophys.,
2012
Jun
, 31 (153-62).
621
Parikh A
et al.
Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2.
Heart Rhythm,
2012
Jun
, 9 (953-60).
622
De Conti L
et al.
Complexities of 5'splice site definition: implications in clinical analyses.
RNA Biol,
2012
Jun
, 9 (911-23).
623
Kulzer M
et al.
Inhibition of cardiac Kir2.1-2.3 channels by beta3 adrenoreceptor antagonist SR 59230A.
Biochem. Biophys. Res. Commun.,
2012
Jul
27
, 424 (315-20).
624
Zhang H
et al.
Modulation of hERG potassium channel gating normalizes action potential duration prolonged by dysfunctional KCNQ1 potassium channel.
Proc. Natl. Acad. Sci. U.S.A.,
2012
Jul
17
, 109 (11866-71).
625
Hayashi M
et al.
An intermediate-conductance Ca2+-activated K+ channel is important for secretion in pancreatic duct cells.
Am. J. Physiol., Cell Physiol.,
2012
Jul
15
, 303 (C151-9).
626
Park MH
et al.
Acute alteration of cardiac ECG, action potential, I(Kr) and the human ether-a-go-go-related gene (hERG) K+ channel by PCB 126 and PCB 77.
Toxicol. Appl. Pharmacol.,
2012
Jul
1
, 262 (60-9).
627
Ivachtchenko AV
et al.
Antagonists of 5-HT₆ receptors. Substituted 3-(phenylsulfonyl)pyrazolo[1,5-a]pyrido[3,4-e]pyrimidines and 3-(phenylsulfonyl)pyrazolo[1,5-a]pyrido[4,3-d]pyrimidines-Synthesis and 'structure-activity' relationship.
Bioorg. Med. Chem. Lett.,
2012
Jul
1
, 22 (4273-80).
628
Apud JA
et al.
Genetic variation in KCNH2 associated with expression in the brain of a unique hERG isoform modulates treatment response in patients with schizophrenia.
Am J Psychiatry,
2012
Jul
1
, 169 (725-34).
629
Jasper A
et al.
Microwave assisted synthesis of spirocyclic pyrrolidines -σ1 receptor ligands with modified benzene-N-distance.
Eur J Med Chem,
2012
Jul
, 53 (327-36).
630
Vandenberg JI
et al.
hERG K(+) channels: structure, function, and clinical significance.
Physiol. Rev.,
2012
Jul
, 92 (1393-478).
631
Vigneault P
et al.
Iloperidone (Fanapt®), a novel atypical antipsychotic, is a potent HERG blocker and delays cardiac ventricular repolarization at clinically relevant concentration.
Pharmacol. Res.,
2012
Jul
, 66 (60-5).
632
Fujii M
et al.
Development of recombinant cell line co-expressing mutated Nav1.5, Kir2.1, and hERG for the safety assay of drug candidates.
J Biomol Screen,
2012
Jul
, 17 (773-84).
633
Moorthy NS
et al.
Analysis of van der Waals surface area properties for human ether-a-go-go-related gene blocking activity: computational study on structurally diverse compounds.
SAR QSAR Environ Res,
2012
Jul
, 23 (521-36).
634
Crotti L
et al.
Torsades de pointes following acute myocardial infarction: evidence for a deadly link with a common genetic variant.
Heart Rhythm,
2012
Jul
, 9 (1104-12).
635
Sroubek J
et al.
The use of Bcl-2 over-expression to stabilize hybridomas specific to the HERG potassium channel.
J. Immunol. Methods,
2012
Jan
31
, 375 (215-22).
636
Eichenbaum G
et al.
Role of Mixed Ion Channel Effects in the Cardiovascular Safety Assessment of the Novel Anti-MRSA Fluoroquinolone JNJ-Q2.
,
2012
Jan
31
, ().
637
Hu CW
et al.
Curcumin inhibits hERG potassium channels in vitro.
Toxicol. Lett.,
2012
Jan
25
, 208 (192-6).
638
Vilums M
et al.
Understanding of molecular substructures that contribute to hERG K+ channel blockade: synthesis and biological evaluation of E-4031 analogues.
ChemMedChem,
2012
Jan
2
, 7 (107-13).
639
McCauley JP
et al.
Multiparameter exploration of piperazine derivatives as δ-opioid receptor agonists for CNS indications.
Bioorg. Med. Chem. Lett.,
2012
Jan
15
, 22 (1169-73).
640
Nguyen HN
et al.
Discovery and optimization of aminopyrimidinones as potent and state-dependent Nav1.7 antagonists.
Bioorg. Med. Chem. Lett.,
2012
Jan
15
, 22 (1055-60).
641
Becknell NC
et al.
Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists.
Bioorg. Med. Chem. Lett.,
2012
Jan
1
, 22 (186-9).
642
Sundar BG
et al.
Novel brain penetrant benzofuropiperidine 5-HT₆ receptor antagonists.
Bioorg. Med. Chem. Lett.,
2012
Jan
1
, 22 (120-3).
643
Puppala D
et al.
Comparative gene expression profiling in human-induced pluripotent stem cell--derived cardiocytes and human and cynomolgus heart tissue.
Toxicol. Sci.,
2012
Jan
, 131 (292-301).
644
Krishnan Y
et al.
Partially dominant mutant channel defect corresponding with intermediate LQT2 phenotype.
Pacing Clin Electrophysiol,
2012
Jan
, 35 (3-16).
645
Hjaeresen ML
et al.
Time course and duration of changes in Kv7.2 and Kv11.1 mRNA expression in the hippocampus and piriform cortex following electroconvulsive stimulations.
Brain Stimul,
2012
Jan
, 5 (55-60).
646
Huang X
et al.
Comparative effects of Guanfu base A and Guanfu base G on HERG K+ channel.
J. Cardiovasc. Pharmacol.,
2012
Jan
, 59 (77-83).
647
El Harchi A
et al.
Molecular determinants of hERG potassium channel inhibition by disopyramide.
J. Mol. Cell. Cardiol.,
2012
Jan
, 52 (185-95).
648
649
Wu SN
et al.
The inhibition by di(2-ethylhexyl)-phthalate of erg-mediated K(+) current in pituitary tumor (GH (3)) cells.
,
2012
Feb
8
, ().
650
Yamakawa Y
et al.
Pharmacophore modeling for hERG channel facilitation.
Biochem. Biophys. Res. Commun.,
2012
Feb
3
, 418 (161-6).
651
Aidery P
et al.
Identification and functional characterization of the novel human ether-a-go-go-related gene (hERG) R744P mutant associated with hereditary long QT syndrome 2.
Biochem. Biophys. Res. Commun.,
2012
Feb
24
, 418 (830-5).
652
Liang G
et al.
A β-tryptase inhibitor with a tropanylamide scaffold to improve in vitro stability and to lower hERG channel binding affinity.
Bioorg. Med. Chem. Lett.,
2012
Feb
15
, 22 (1606-10).
653
Cumming JG
et al.
Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis.
Bioorg. Med. Chem. Lett.,
2012
Feb
15
, 22 (1655-9).
654
Jonsson MK
et al.
Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG.
,
2012
Feb
14
, ().
655
Polak S
et al.
Slow delayed rectifying potassium current (I(Ks) ) - analysis of the in vitro inhibition data and predictive model development.
,
2012
Feb
14
, ().
656
Yang X
et al.
Oestrogen upregulates L-type Ca²⁺ channels via oestrogen-receptor- by a regional genomic mechanism in female rabbit hearts.
J. Physiol. (Lond.),
2012
Feb
1
, 590 (493-508).
657
Zhang R
et al.
Human ether-à-go-go-related gene expression is essential for cisplatin to induce apoptosis in human gastric cancer.
Oncol. Rep.,
2012
Feb
, 27 (433-40).
658
Dennis AT
et al.
Molecular determinants of pentamidine-induced hERG trafficking inhibition.
Mol. Pharmacol.,
2012
Feb
, 81 (198-209).
659
Zhang M
et al.
KCNE2 protein is more abundant in ventricles than in atria and can accelerate hERG protein degradation in a phosphorylation-dependent manner.
Am. J. Physiol. Heart Circ. Physiol.,
2012
Feb
, 302 (H910-22).
660
Baaklini I
et al.
The DNAJA2 substrate release mechanism is essential for chaperone-mediated folding.
J. Biol. Chem.,
2012
Dec
7
, 287 (41939-54).
661
Wang X
et al.
Positive selection-guided mutational analysis revealing two key functional sites of scorpion ERG K(+) channel toxins.
Biochem. Biophys. Res. Commun.,
2012
Dec
7
, 429 (111-6).
662
Pareja K
et al.
Role of the activation gate in determining the extracellular potassium dependency of block of HERG by trapped drugs.
Channels (Austin),
2012
Dec
6
, 7 ().
663
González Cabrera D
et al.
Structure-activity relationship studies of orally active antimalarial 3,5-substituted 2-aminopyridines.
J. Med. Chem.,
2012
Dec
27
, 55 (11022-30).
664
Schweikart K
et al.
The effects of jaspamide on human cardiomyocyte function and cardiac ion channel activity.
Toxicol In Vitro,
2012
Dec
20
, 27 (745-751).
665
Ishii K
et al.
Endocytic regulation of voltage-dependent potassium channels in the heart.
J. Pharmacol. Sci.,
2012
Dec
18
, 120 (264-9).
666
Organ-Darling LE
et al.
Interactions between hERG and KCNQ1 α-subunits are mediated by their C-termini and modulated by cAMP.
Am. J. Physiol. Heart Circ. Physiol.,
2012
Dec
15
, ().
667
Campbell K
et al.
Spatial gradients in action potential duration created by regional magnetofection of hERG are a substrate for wavebreak and turbulent propagation in cardiomyocyte monolayers.
J. Physiol. (Lond.),
2012
Dec
15
, 590 (6363-79).
668
Tanis VM
et al.
Azabenzthiazole inhibitors of leukotriene A₄ hydrolase.
Bioorg. Med. Chem. Lett.,
2012
Dec
15
, 22 (7504-11).
669
Balijepalli SY
et al.
Mechanism of Loss of Kv11.1 K+ Current in Mutant T421M-Kv11.1-Expressing Rat Ventricular Myocytes: Interaction of Trafficking and Gating.
Circulation,
2012
Dec
11
, 126 (2809-18).
670
Warner B
Genetic variation in KCNH2 and a unique hERG isoform in patients with schizophrenia: efficacy-safety link.
Am J Psychiatry,
2012
Dec
1
, 169 (1318; author reply 1318-9).
671
Gaunt TR
et al.
Integration of Genetics into a Systems Model of Electrocardiographic Traits Using HumanCVD BeadChip.
Circ Cardiovasc Genet,
2012
Dec
1
, 5 (630-8).
672
Peigneur S
et al.
A natural point mutation changes both target selectivity and mechanism of action of sea anemone toxins.
FASEB J.,
2012
Dec
, 26 (5141-51).
673
Ng HQ
et al.
Purification and structural characterization of the voltage-sensor domain of the hERG potassium channel.
Protein Expr. Purif.,
2012
Dec
, 86 (98-104).
674
Peters MF
et al.
Evaluation of cellular impedance measures of cardiomyocyte cultures for drug screening applications.
Assay Drug Dev Technol,
2012
Dec
, 10 (525-32).
675
Reck F
et al.
Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile.
J. Med. Chem.,
2012
Aug
9
, 55 (6916-33).
676
Butini S
et al.
Discovery of potent inhibitors of human and mouse fatty acid amide hydrolases.
J. Med. Chem.,
2012
Aug
9
, 55 (6898-915).
677
Broccatelli F
et al.
QSAR modeling and data mining link Torsades de Pointes risk to the interplay of extent of metabolism, active transport, and HERG liability.
Mol. Pharm.,
2012
Aug
6
, 9 (2290-301).
678
Liu Y
et al.
Effects of the natural flavone trimethylapigenin on cardiac potassium currents.
Biochem. Pharmacol.,
2012
Aug
15
, 84 (498-506).
679
Twiner MJ
et al.
Marine Algal Toxin Azaspiracid Is an Open-State Blocker of hERG Potassium Channels.
Chem. Res. Toxicol.,
2012
Aug
10
, ().
680
Chen L
et al.
Confirmation of a proarrhythmic risk underlying the clinical use of common Chinese herbal intravenous injections.
J Ethnopharmacol,
2012
Aug
1
, 142 (829-35).
681
Sams AG
et al.
Hit-to-lead investigation of a series of novel combined dopamine D2 and muscarinic M1 receptor ligands with putative antipsychotic and pro-cognitive potential.
Bioorg. Med. Chem. Lett.,
2012
Aug
1
, 22 (5134-40).
682
Zheng F
et al.
Human ether-a-go-go-related gene K+ channels regulate shedding of leukemia cell-derived microvesicles.
Leuk. Lymphoma,
2012
Aug
, 53 (1592-8).
683
Kruse M
et al.
Regulation of voltage-gated potassium channels by PI(4,5)P2.
J. Gen. Physiol.,
2012
Aug
, 140 (189-205).
684
Durdagi S
et al.
Structure-guided topographic mapping and mutagenesis to elucidate binding sites for the human ether-a-go-go-related gene 1 potassium channel (KCNH2) activator NS1643.
J. Pharmacol. Exp. Ther.,
2012
Aug
, 342 (441-52).
685
Gustina AS
et al.
HERG potassium channel regulation by the N-terminal eag domain.
Cell. Signal.,
2012
Aug
, 24 (1592-8).
686
Chinushi M
et al.
Exercise-related QT interval shortening with a peaked T wave in a healthy boy with a family history of sudden cardiac death.
Pacing Clin Electrophysiol,
2012
Aug
, 35 (e239-42).
687
Krishnan Y
et al.
Mechanisms underlying the protein-kinase mediated regulation of the HERG potassium channel synthesis.
Biochim. Biophys. Acta,
2012
Aug
, 1823 (1273-84).
688
Jiménez-Vargas JM
et al.
Toxin modulators and blockers of hERG K(+) channels.
,
2012
Apr
5
, ().
689
Vedani A
et al.
VirtualToxLab - A platform for estimating the toxic potential of drugs, chemicals and natural products.
,
2012
Apr
4
, ().
690
Cavalli A
et al.
Computational design and discovery of "minimally structured" hERG blockers.
J. Med. Chem.,
2012
Apr
26
, 55 (4010-4).
691
Liu X
et al.
Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers.
Life Sci.,
2012
Apr
20
, 90 (607-11).
692
Wang S
et al.
ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage.
Mol. Pharm.,
2012
Apr
2
, 9 (996-1010).
693
Zamorano-León JJ
et al.
KCNH2 Gene Mutation: A Potential Link Between Epilepsy and Long QT-2 Syndrome.
,
2012
Apr
19
, ().
694
Vigneault P
et al.
Galantamine (Reminyl) delays cardiac ventricular repolarization and prolongs the QT interval by blocking the HERG current.
Eur. J. Pharmacol.,
2012
Apr
15
, 681 (68-74).
695
Finlay HJ
et al.
Discovery of ((S)-5-(methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S)-2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone as a potent and selective I(Kur) inhibitor.
J. Med. Chem.,
2012
Apr
12
, 55 (3036-48).
696
Vachal P
et al.
1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.
J. Med. Chem.,
2012
Apr
12
, 55 (2945-59).
697
Handzlik J
et al.
Antiarrhythmic properties of phenylpiperazine derivatives of phenytoin with α₁-adrenoceptor affinities.
Bioorg. Med. Chem.,
2012
Apr
1
, 20 (2290-303).
698
Son HJ
et al.
A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP.
Br. J. Pharmacol.,
2012
Apr
, 165 (2213-27).
699
Ababneh D
et al.
Antidepressants Cause Bradycardia and Heart Block in GD 13 Rat Embryos In Vitro.
Birth Defects Res. B Dev. Reprod. Toxicol.,
2012
Apr
, 95 (184-93).
700
Cheng H
et al.
High potency inhibition of hERG potassium channels by the sodium-calcium exchange inhibitor KB-R7943.
Br. J. Pharmacol.,
2012
Apr
, 165 (2260-73).
701
Alonso M
et al.
Anti-obesity efficacy of LH-21, a cannabinoid CB(1) receptor antagonist with poor brain penetration, in diet-induced obese rats.
Br. J. Pharmacol.,
2012
Apr
, 165 (2274-91).
702
Carretero L
et al.
Cell type influences the molecular mechanisms involved in hormonal regulation of ERG K+ channels.
Pflugers Arch.,
2012
Apr
, 463 (685-702).
703
Misner DL
et al.
Investigation of mechanism of drug-induced cardiac injury and torsades de pointes in cynomolgus monkeys.
Br. J. Pharmacol.,
2012
Apr
, 165 (2771-86).
704
Hirano-Iwata A
et al.
Stable lipid bilayers based on micro- and nano-fabrication as a platform for recording ion-channel activities.
Anal Sci,
2012
, 28 (1049-57).
705
Ceccarini L
et al.
Ion conduction through the hERG potassium channel.
PLoS ONE,
2012
, 7 (e49017).
706
Hoekstra M
et al.
Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias.
Front Physiol,
2012
, 3 (346).
707
Sung DJ
et al.
Blockade of K+ and Ca2+ channels by azole antifungal agents in neonatal rat ventricular myocytes.
Biol. Pharm. Bull.,
2012
, 35 (1469-75).
708
Moreno C
et al.
Polyunsaturated Fatty acids modify the gating of kv channels.
Front Pharmacol,
2012
, 3 (163).
709
Polak S
et al.
Tox-database.net: a curated resource for data describing chemical triggered in vitro cardiac ion channels inhibition.
BMC Pharmacol Toxicol,
2012
, 13 (6).
710
Stump MR
et al.
Isoform-specific dominant-negative effects associated with hERG1 G628S mutation in long QT syndrome.
PLoS ONE,
2012
, 7 (e42552).
711
Ng CA
et al.
The S4-S5 linker acts as a signal integrator for HERG K+ channel activation and deactivation gating.
PLoS ONE,
2012
, 7 (e31640).
712
Dong ZX
et al.
Comparative effects of liensinine and neferine on the human ether-a-go-go-related gene potassium channel and pharmacological activity analysis.
Cell. Physiol. Biochem.,
2012
, 29 (431-42).
713
Harley CA
et al.
Changes in channel trafficking and protein stability caused by LQT2 mutations in the PAS domain of the HERG channel.
PLoS ONE,
2012
, 7 (e32654).
714
Wang Y
et al.
Trafficking-deficient G572R-hERG and E637K-hERG activate stress and clearance pathways in endoplasmic reticulum.
PLoS ONE,
2012
, 7 (e29885).
715
Cheng YM
et al.
Voltage-dependent gating of HERG potassium channels.
Front Pharmacol,
2012
, 3 (83).
716
Polonchuk L
Toward a New Gold Standard for Early Safety: Automated Temperature-Controlled hERG Test on the PatchLiner.
Front Pharmacol,
2012
, 3 (3).
717
Yang XF
et al.
The antibody targeting the e314 Peptide of human kv1.3 pore region serves as a novel, potent and specific channel blocker.
PLoS ONE,
2012
, 7 (e36379).
718
Nishimoto O
et al.
Peripartum cardiomyopathy presenting with syncope due to Torsades de pointes: a case of long QT syndrome with a novel KCNH2 mutation.
Intern. Med.,
2012
, 51 (461-4).
719
Ferro F
et al.
Long-chain acylcarnitines regulate the hERG channel.
PLoS ONE,
2012
, 7 (e41686).
720
Köpfer DA
et al.
A molecular switch driving inactivation in the cardiac K+ channel HERG.
PLoS ONE,
2012
, 7 (e41023).
721
Bilet A
et al.
Effects of the small molecule HERG activator NS1643 on Kv11.3 channels.
PLoS ONE,
2012
, 7 (e50886).
722
Lazarczyk MJ
et al.
Selective acquired long QT syndrome (saLQTS) upon risperidone treatment.
BMC Psychiatry,
2012
, 12 (220).
723
Heide J
et al.
The schizophrenia-associated Kv11.1-3.1 isoform results in reduced current accumulation during repetitive brief depolarizations.
PLoS ONE,
2012
, 7 (e45624).
724
Munoz C
et al.
Stimulation of HERG channel activity by β-catenin.
PLoS ONE,
2012
, 7 (e43353).
725
Xu XH
et al.
Allitridi inhibits multiple cardiac potassium channels expressed in HEK 293 cells.
PLoS ONE,
2012
, 7 (e51550).
726
Sato A
et al.
Long QT syndrome with nocturnal cardiac events caused by a KCNH2 missense mutation (G604S).
Intern. Med.,
2012
, 51 (1857-60).
727
Moric-Janiszewska E
et al.
Molecular diagnostics of families with long-QT syndrome.
Cardiol J,
2012
, 19 (159-67).
728
Takahara A
et al.
Effects of the antitussive drug cloperastine on ventricular repolarization in halothane-anesthetized guinea pigs.
J. Pharmacol. Sci.,
2012
, 120 (165-75).
729
El Harchi A
et al.
Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel.
PLoS ONE,
2012
, 7 (e52451).
730
Sato A
et al.
Benign premature ventricular complexes from the right ventricular outflow tract triggered polymorphic ventricular tachycardia in a latent type 2 LQTS patient.
Intern. Med.,
2012
, 51 (3261-5).
731
Zhang GH
et al.
Cytocompatible performance of thermosensitive poly(N-isopropylacrylamide) nanoparticles.
J Biomater Sci Polym Ed,
2012
, 23 (1569-78).
732
Qu Y
et al.
hERG potency estimates based upon dose solution analysis: What have we learned?
J Pharmacol Toxicol Methods,
2011 Nov-Dec
, 64 (251-7).
733
Champeroux P
et al.
A step towards characterisation of electrophysiological profile of torsadogenic drugs.
J Pharmacol Toxicol Methods,
2011 May-Jun
, 63 (269-78).
734
Watson KJ
et al.
Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys.
J Pharmacol Toxicol Methods,
2011 May-Jun
, 63 (304-13).
735
Patoine D
et al.
A novel KCNQ1 variant (L203P) associated with torsades de pointes-related syncope in a Steinert syndrome patient.
Can J Cardiol,
2011 Mar-Apr
, 27 (263.e5-12).
736
Dennis AT
et al.
Antidepressant-induced ubiquitination and degradation of the cardiac potassium channel hERG.
J. Biol. Chem.,
2011
Sep
30
, 286 (34413-25).
737
Zhang X
et al.
Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.
Bioorg. Med. Chem. Lett.,
2011
Sep
15
, 21 (5577-82).
738
Geng B
et al.
Exploring Left-Hand-Side substitutions in the benzoxazinone series of 4-amino-piperidine bacterial type IIa topoisomerase inhibitors.
Bioorg. Med. Chem. Lett.,
2011
Sep
15
, 21 (5432-5).
739
Abi-Gerges N
et al.
hERG subunit composition determines differential drug sensitivity.
Br. J. Pharmacol.,
2011
Sep
, 164 (419-32).
740
Lee BH
et al.
Effects of the histamine H(1) receptor antagonist hydroxyzine on hERG K(+) channels and cardiac action potential duration.
Acta Pharmacol. Sin.,
2011
Sep
, 32 (1128-37).
741
Guo J
et al.
Interaction between the cardiac rapidly (IKr) and slowly (IKs) activating delayed rectifier potassium channels revealed by low K+-induced hERG endocytic degradation.
J. Biol. Chem.,
2011
Oct
7
, 286 (34664-74).
742
van der Stelt M
et al.
Discovery and Optimization of 1-(4-(Pyridin-2-yl)benzyl)imidazolidine-2,4-dione Derivatives As a Novel Class of Selective Cannabinoid CB2 Receptor Agonists.
J. Med. Chem.,
2011
Oct
27
, 54 (7350-62).
743
Banasavadi-Siddegowda YK
et al.
FKBP38 Peptidylprolyl isomerase promotes the folding of cystic fibrosis transmembrane conductance regulator in the endoplasmic reticulum.
,
2011
Oct
26
, ().
744
Donovan BT
et al.
Utility of frozen cell lines in medium throughput electrophysiology screening of hERG and Na(V)1.5 blockade.
,
2011
Oct
2
, ().
745
Metz M
et al.
Prospective CCR5 small molecule antagonist compound design using a combined mutagenesis/modeling approach.
J. Am. Chem. Soc.,
2011
Oct
19
, 133 (16477-85).
746
Saba S
et al.
Cardiac Levels of NOS1AP RNA from Right Ventricular Tissue Recovered During Lead Extraction.
,
2011
Oct
18
, ().
747
Zhou Y
et al.
Ionic mechanisms underlying cardiac toxicity of the organochloride solvent trichloromethane.
,
2011
Oct
17
, ().
748
Schwoerer AP
et al.
Bupivacaine Destabilizes Action Potential Duration in Cellular and Computational Models of Long QT Syndrome 1.
,
2011
Oct
14
, ().
749
Woo HM
et al.
Synthesis and biological evaluation of 4-piperidinecarboxylate and 4-piperidinecyanide derivatives for T-type calcium channel blockers.
Bioorg. Med. Chem. Lett.,
2011
Oct
1
, 21 (5910-5).
750
Müller A
et al.
Synthesis of a series of γ-amino alcohols comprising an N-methyl isoindoline moiety and their evaluation as NMDA receptor antagonists.
Bioorg. Med. Chem. Lett.,
2011
Oct
1
, 21 (5795-9).
751
Nof E
et al.
LQT5 masquerading as LQT2: a dominant negative effect of KCNE1-D85N rare polymorphism on KCNH2 current.
Europace,
2011
Oct
, 13 (1478-83).
752
Jeon SH
et al.
Effects of nortriptyline on QT prolongation: a safety pharmacology study.
Hum Exp Toxicol,
2011
Oct
, 30 (1649-56).
753
Migdalovich D
et al.
Mutation and gender-specific risk in type 2 long QT syndrome: implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome.
Heart Rhythm,
2011
Oct
, 8 (1537-43).
754
Barsheshet A
et al.
Risk of syncope in family members who are genotype-negative for a family-associated long-QT syndrome mutation.
Circ Cardiovasc Genet,
2011
Oct
, 4 (491-9).
755
Narayana Moorthy NS
et al.
In silico-based structural analysis of arylthiophene derivatives for FTase inhibitory activity, hERG, and other toxic effects.
J Biomol Screen,
2011
Oct
, 16 (1037-46).
756
Garg V
et al.
Molecular determinants for activation of human ether-à-go-go-related gene 1 potassium channels by 3-nitro-n-(4-phenoxyphenyl) benzamide.
Mol. Pharmacol.,
2011
Oct
, 80 (630-7).
757
Tester DJ
et al.
Unexplained drownings and the cardiac channelopathies: a molecular autopsy series.
Mayo Clin. Proc.,
2011
Oct
, 86 (941-7).
758
Wang RR
et al.
The effects of paeoniflorin monomer of a Chinese herb on cardiac ion channels.
Chin. Med. J.,
2011
Oct
, 124 (3105-11).
759
Kilinc OU
et al.
Successful Elimination of Significant Arrhythmia Burden with Flecainide in an Adolescent with Long QT Syndrome Type 3.
,
2011
Nov
30
, ().
760
Lahti AL
et al.
Human disease model for long QT syndrome type 2 using iPS cells demonstrates arrhythmogenic characteristics in cell culture.
,
2011
Nov
3
, ().
761
Aoki Y
et al.
Role of ion channels in sepsis-induced atrial tachyarrhythmias in guinea pigs.
,
2011
Nov
3
, ().
762
Du-Cuny L
et al.
A critical assessment of combined ligand- and structure-based approaches to HERG channel blocker modeling.
J Chem Inf Model,
2011
Nov
28
, 51 (2948-60).
763
Reck F
et al.
Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity.
J. Med. Chem.,
2011
Nov
24
, 54 (7834-47).
764
Wang W
et al.
7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.
Bioorg. Med. Chem. Lett.,
2011
Nov
15
, 21 (6646-51).
765
Honda M
et al.
Electrophysiological characterization of cardiomyocytes derived from human induced pluripotent stem cells.
J. Pharmacol. Sci.,
2011
Nov
15
, 117 (149-59).
766
Ferrer T
et al.
Molecular Coupling in the Human ether-a-go-go-related gene-1 (hERG1) K+ Channel Inactivation Pathway.
J. Biol. Chem.,
2011
Nov
11
, 286 (39091-9).
767
Glassmeier G
et al.
Inhibition of HERG1 K(+) channel protein expression decreases cell proliferation of human small cell lung cancer cells.
,
2011
Nov
11
, ().
768
Furutani K
et al.
A mechanism underlying compound-induced voltage shift in the current activation of hERG by antiarrhythmic agents.
Biochem. Biophys. Res. Commun.,
2011
Nov
11
, 415 (141-6).
769
González Cabrera D
et al.
Novel orally active antimalarial thiazoles.
J. Med. Chem.,
2011
Nov
10
, 54 (7713-9).
770
Fan X
et al.
Novel electropharmacological activity of amiodarone on human HCN channels heterologously expressed in the Xenopus oocytes.
Eur. J. Pharmacol.,
2011
Nov
1
, 669 (15-23).
771
Lange A
et al.
Neuronal differentiation by indomethacin and IBMX inhibits proliferation of small cell lung cancer cells in vitro.
Lung Cancer,
2011
Nov
, 74 (178-87).
772
Bai YL
et al.
HIV Tat protein inhibits hERG K+ channels: a potential mechanism of HIV infection induced LQTs.
J. Mol. Cell. Cardiol.,
2011
Nov
, 51 (876-80).
773
Schuster AM
et al.
Strong activation of ether-à-go-go-related gene 1 K+ channel isoforms by NS1643 in human embryonic kidney 293 and Chinese hamster ovary cells.
Mol. Pharmacol.,
2011
Nov
, 80 (930-42).
774
Shang BY
et al.
[Lidamycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs].
Yao Xue Xue Bao,
2011
Nov
, 46 (1321-5).
775
de la Peña P
et al.
Demonstration of physical proximity between the N terminus and the S4-S5 linker of the human ether-a-go-go-related gene (hERG) potassium channel.
J. Biol. Chem.,
2011
May
27
, 286 (19065-75).
776
Wiles JA
et al.
Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
J. Med. Chem.,
2011
May
12
, 54 (3418-25).
777
Golden AP
et al.
IonFlux: A Microfluidic Patch Clamp System Evaluated with Human Ether-à-go-go Related Gene Channel Physiology and Pharmacology.
,
2011
May
11
, ().
778
Xia M
et al.
Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels.
Toxicol. Appl. Pharmacol.,
2011
May
1
, 252 (250-8).
779
Zheng F
et al.
Role of hERG1 K(+) channels in leukemia cells as a positive regulator in SDF-1a-induced proliferation.
Hematology,
2011
May
, 16 (177-84).
780
Ando F
et al.
Synergic effects of β-estradiol and erythromycin on hERG currents.
J. Membr. Biol.,
2011
May
, 241 (31-8).
781
Soma K
et al.
Abundant expression of KCNE1 in the left ventricle of the miniature pig.
Heart Vessels,
2011
May
, 26 (353-6).
782
Schramm A
et al.
HERG channel inhibitors in extracts of Coptidis rhizoma.
Planta Med.,
2011
May
, 77 (692-7).
783
Benson AP
et al.
Quantitative prediction of the arrhythmogenic effects of de novo hERG mutations in computational models of human ventricular tissues.
Eur. Biophys. J.,
2011
May
, 40 (627-39).
784
Guo J
et al.
Involvement of caveolin in probucol-induced reduction in hERG plasma-membrane expression.
Mol. Pharmacol.,
2011
May
, 79 (806-13).
785
Ouillé A
et al.
ION CHANNEL BLOCKING PROFILE OF COMPOUNDS WITH REPORTED TORSADOGENIC EFFECTS: WHAT CAN BE LEARNED?
,
2011
Mar
8
, ().
786
Luker T
et al.
Zwitterionic CRTh2 antagonists.
J. Med. Chem.,
2011
Mar
24
, 54 (1779-88).
787
Matsa E
et al.
Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation.
,
2011
Mar
2
, ().
788
Novotny T
et al.
Mutation Analysis Ion Channel Genes Ventricular Fibrillation Survivors with Coronary Artery Disease.
,
2011
Mar
16
, ().
789
Huang N
et al.
The EGFP/hERG fusion protein alter the electrophysiological properties of hERG channels in HEK293 cells.
Cell Biol. Int.,
2011
Mar
1
, 35 (193-9).
790
Gustina AS
et al.
hERG potassium channel gating is mediated by N- and C-terminal region interactions.
J. Gen. Physiol.,
2011
Mar
, 137 (315-25).
791
Sun Y
et al.
A novel mutation in the KCNH2 gene associated with short QT syndrome.
J. Mol. Cell. Cardiol.,
2011
Mar
, 50 (433-41).
792
Forgo P
et al.
Diterpene alkaloids from Aconitum anthora and assessment of the hERG-inhibiting ability of Aconitum alkaloids.
Planta Med.,
2011
Mar
, 77 (368-73).
793
Skinner JR
et al.
Prospective, population-based long QT molecular autopsy study of postmortem negative sudden death in 1 to 40 year olds.
Heart Rhythm,
2011
Mar
, 8 (412-9).
794
Amorós I
et al.
Functional effects of a missense mutation in HERG associated with type 2 long QT syndrome.
Heart Rhythm,
2011
Mar
, 8 (463-70).
795
Kazmierski WM
et al.
Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile.
J. Med. Chem.,
2011
Jun
9
, 54 (3756-67).
796
Zhao J
et al.
Cyclovirobuxine D inhibits the currents of HERG potassium channels stably expressed in HEK293 cells.
Eur. J. Pharmacol.,
2011
Jun
25
, 660 (259-67).
797
Ducray R
et al.
Novel imidazo[1,2-a]pyridine based inhibitors of the IGF-1 receptor tyrosine kinase: Optimization of the aniline.
,
2011
Jun
25
, ().
798
Shimizu W
et al.
Phenotypic manifestations of mutations in genes encoding subunits of cardiac potassium channels.
Circ. Res.,
2011
Jun
24
, 109 (97-109).
799
Gianulis EC
et al.
Rescue of aberrant gating by a genetically encoded PAS (Per-Arnt-Sim) domain in several long QT syndrome mutant human ether-á-go-go-related gene potassium channels.
J. Biol. Chem.,
2011
Jun
24
, 286 (22160-9).
800
Chambers KF
et al.
Stromal upregulation of lateral epithelial adhesions: Gene expression analysis of signalling pathways in prostate epithelium.
,
2011
Jun
22
, 18 (45).
801
Buber J
et al.
Risk of recurrent cardiac events after onset of menopause in women with congenital long-QT syndrome types 1 and 2.
Circulation,
2011
Jun
21
, 123 (2784-91).
802
Sroubek J
et al.
Protein kinase A activity at the endoplasmic reticulum surface is responsible for augmentation of human ether-a-go-go-related gene product (HERG).
J. Biol. Chem.,
2011
Jun
17
, 286 (21927-36).
803
Shultz MD
et al.
Optimization of the in Vitro Cardiac Safety of Hydroxamate-Based Histone Deacetylase Inhibitors.
,
2011
Jun
17
, ().
804
Crottes D
et al.
Sigma 1 receptor regulates HERG channel expression through a post-translational mechanism in leukemic cells.
,
2011
Jun
16
, ().
805
Liu Y
et al.
The role of the 4''-hydroxyl on motilin agonist potency in the 9-dihydroerythromycin series.
Bioorg. Med. Chem. Lett.,
2011
Jun
15
, 21 (3712-4).
806
Brown DG
et al.
2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.
Bioorg. Med. Chem. Lett.,
2011
Jun
1
, 21 (3399-403).
807
Taboureau O
et al.
In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology.
Comb. Chem. High Throughput Screen.,
2011
Jun
1
, 14 (375-87).
808
Zhou PZ
et al.
Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules.
Acta Pharmacol. Sin.,
2011
Jun
, 32 (781-8).
809
Vigneault P
et al.
Prolongation of cardiac ventricular repolarization under paliperidone: how and how much?
J. Cardiovasc. Pharmacol.,
2011
Jun
, 57 (690-5).
810
Choi KH
et al.
hERG channel blockade by externally applied quaternary ammonium derivatives.
Biochim. Biophys. Acta,
2011
Jun
, 1808 (1560-6).
811
Lin YL
et al.
Electrophysiologic, pharmacokinetic, and pharmacodynamic values indicating a higher risk of torsades de pointes.
J Clin Pharmacol,
2011
Jun
, 51 (819-29).
812
Johansson A
Recent progress in the discovery of melanin-concentrating hormone 1-receptor antagonists.
Expert Opin Ther Pat,
2011
Jun
, 21 (905-25).
813
Hreiche R
et al.
Lengthening of cardiac repolarization in isolated guinea pigs hearts by sequential or concomitant administration of two IKr blockers.
J Pharm Sci,
2011
Jun
, 100 (2469-81).
814
Mo J
et al.
Altered gene expression by low-dose arsenic exposure in humans and cultured cardiomyocytes: assessment by real-time PCR arrays.
Int J Environ Res Public Health,
2011
Jun
, 8 (2090-108).
816
Shao L
et al.
Synthesis and Pharmacological Characterization of Bicyclic Triple Reuptake Inhibitor 3-Aryl Octahydrocyclopenta[c]pyrrole Analogues.
,
2011
Jul
8
, ().
817
Szabó G
et al.
Enhanced Repolarization Capacity: New Potential Antiarrhythmic Strategy Based on hERG Channel Activation.
,
2011
Jul
21
, ().
818
Zhang YH
et al.
The hERG K(+) channel S4 domain L532P mutation: Characterization at 37°C.
,
2011
Jul
14
, ().
819
Bregman H
et al.
Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain.
J. Med. Chem.,
2011
Jul
14
, 54 (4427-45).
820
Boukharta L
et al.
Computer simulations of structure-activity relationships for HERG channel blockers.
Biochemistry,
2011
Jul
12
, 50 (6146-56).
821
Utech T
et al.
Synthesis and pharmacological evaluation of a potent and selective σ1 receptor antagonist with high antiallodynic activity.
Arch. Pharm. (Weinheim),
2011
Jul
, 344 (415-21).
822
Smith JL
et al.
Trafficking-deficient hERG K⁺ channels linked to long QT syndrome are regulated by a microtubule-dependent quality control compartment in the ER.
Am. J. Physiol., Cell Physiol.,
2011
Jul
, 301 (C75-85).
823
Couderc JP
et al.
T-wave morphology abnormalities in benign, potent, and arrhythmogenic I(kr) inhibition.
Heart Rhythm,
2011
Jul
, 8 (1036-43).
824
Wallace JL
et al.
The life and death of breast cancer cells: proposing a role for the effects of phytoestrogens on potassium channels.
J. Membr. Biol.,
2011
Jul
, 242 (53-67).
825
Hayakawa EH
et al.
Comparison of protein behavior between wild-type and G601S hERG in living cells by fluorescence correlation spectroscopy.
J Physiol Sci,
2011
Jul
, 61 (313-9).
826
Peal DS
et al.
Novel chemical suppressors of long QT syndrome identified by an in vivo functional screen.
Circulation,
2011
Jan
4
, 123 (23-30).
827
Barc J
et al.
Screening for copy number variation in genes associated with the long QT syndrome: clinical relevance.
J. Am. Coll. Cardiol.,
2011
Jan
4
, 57 (40-7).
828
Pillozzi S
et al.
Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers.
Blood,
2011
Jan
20
, 117 (902-14).
829
Obiol-Pardo C
et al.
A Multiscale Simulation System for the Prediction of Drug-Induced Cardiotoxicity.
,
2011
Jan
20
, ().
830
Best JM
et al.
The Small GTPase Rab11b Regulates Degradation of Surface Membrane L-Type Cav1.2 Channels.
,
2011
Jan
19
, ().
831
Itzhaki I
et al.
Modelling the long QT syndrome with induced pluripotent stem cells.
,
2011
Jan
16
, ().
832
Millat G
et al.
Development of a high resolution melting method for the detection of genetic variations in Long QT Syndrome.
Clin. Chim. Acta,
2011
Jan
14
, 412 (203-7).
833
Stupple PA
et al.
An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
J. Med. Chem.,
2011
Jan
13
, 54 (67-77).
834
Han S
et al.
Fluconazole inhibits hERG K(+) channel by direct block and disruption of protein trafficking.
Eur. J. Pharmacol.,
2011
Jan
10
, 650 (138-44).
835
Tye H
et al.
Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.
Bioorg. Med. Chem. Lett.,
2011
Jan
1
, 21 (34-7).
836
Firth AL
et al.
Functional ion channels in human pulmonary artery smooth muscle cells: Voltage-dependent cation channels.
Pulm Circ,
2011
Jan
1
, 1 (48-71).
837
Gong Q
et al.
Inhibition of nonsense-mediated mRNA decay by antisense morpholino oligonucleotides restores functional expression of hERG nonsense and frameshift mutations in long-QT syndrome.
J. Mol. Cell. Cardiol.,
2011
Jan
, 50 (223-9).
838
Grunnet M
et al.
Molecular determinants of human ether-à-go-go-related gene 1 (hERG1) K+ channel activation by NS1643.
Mol. Pharmacol.,
2011
Jan
, 79 (1-9).
839
Bartos DC
et al.
R231C mutation in KCNQ1 causes long QT syndrome type 1 and familial atrial fibrillation.
Heart Rhythm,
2011
Jan
, 8 (48-55).
840
Stump MR
et al.
Multiple splicing defects caused by hERG splice site mutation 2592+1G>A associated with long QT syndrome.
Am. J. Physiol. Heart Circ. Physiol.,
2011
Jan
, 300 (H312-8).
841
Parkman HP
et al.
Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects.
Dig. Dis. Sci.,
2011
Jan
, 56 (115-24).
842
Mirams GR
et al.
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
,
2011
Feb
7
, ().
843
Ernesto C
et al.
[Investigation of ion channel gene variants in patients with long QT syndrome.]
,
2011
Feb
4
, ().
844
Durdagi S
et al.
Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
J Chem Inf Model,
2011
Feb
28
, 51 (463-74).
845
Muskett FW
et al.
Mechanistic insight into human ether-à-go-go-related gene (hERG) K+ channel deactivation gating from the solution structure of the EAG domain.
J. Biol. Chem.,
2011
Feb
25
, 286 (6184-91).
846
Sun T
et al.
The role of monoubiquitination in endocytic degradation of human ether-a-go-go-related gene (hERG) channels under low K+ conditions.
J. Biol. Chem.,
2011
Feb
25
, 286 (6751-9).
847
Li P
et al.
Reciprocal control of hERG stability by Hsp70 and Hsc70 with implication for restoration of LQT2 mutant stability.
Circ. Res.,
2011
Feb
18
, 108 (458-68).
848
Du CY
et al.
Enhanced inhibitory effect of acidosis on hERG potassium channels that incorporate the hERG1b isoform.
Biochem. Biophys. Res. Commun.,
2011
Feb
11
, 405 (222-7).
849
Gintant G
An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation.
Pharmacol. Ther.,
2011
Feb
, 129 (109-19).
850
Sinha N
et al.
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Eur J Med Chem,
2011
Feb
, 46 (618-30).
851
Hu C
et al.
Down-regulation of the human ether-a-go-go-related gene in rat cardiac hypertrophy.
Am. J. Med. Sci.,
2011
Feb
, 341 (119-25).
852
Staudacher I
et al.
hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine.
Naunyn Schmiedebergs Arch. Pharmacol.,
2011
Feb
, 383 (119-39).
853
van Noord C
et al.
Non-cardiovascular drugs that inhibit hERG-encoded potassium channels and risk of sudden cardiac death.
Heart,
2011
Feb
, 97 (215-20).
854
Zhu S
et al.
Molecular diversity and functional evolution of scorpion potassium channel toxins.
Mol. Cell Proteomics,
2011
Feb
, 10 (M110.002832).
855
Bentzen BH
et al.
Pharmacological activation of Kv11.1 in transgenic long QT-1 rabbits.
J. Cardiovasc. Pharmacol.,
2011
Feb
, 57 (223-30).
856
Arcangeli A
et al.
Targeting Ion Channels in Leukemias: A New Challenge for Treatment.
,
2011
Dec
29
, ().
857
Davies MR
et al.
An In silico Canine Cardiac Midmyocardial Action Potential Duration Model as a Tool for Early Drug Safety Assessment.
,
2011
Dec
23
, ().
858
859
860
Brocklehurst KJ
et al.
Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.
Bioorg. Med. Chem. Lett.,
2011
Dec
15
, 21 (7310-6).
861
Yamazaki K
et al.
A novel method of selecting human embryonic stem cell-derived cardiomyocyte clusters for assessment of potential to influence QT interval.
,
2011
Dec
14
, ().
862
Zheng F
et al.
Imatinib has the potential to exert its antileukemia effects by down-regulating hERG1 K(+) channels in chronic myelogenous leukemia.
,
2011
Dec
10
, ().
863
Du F
et al.
hERGCentral: A Large Database to Store, Retrieve, and Analyze Compound-Human Ether-à-go-go Related Gene Channel Interactions to Facilitate Cardiotoxicity Assessment in Drug Development.
Assay Drug Dev Technol,
2011
Dec
, 9 (580-8).
864
Chen J
et al.
A dual mechanism for I(Ks) current reduction by the pathogenic mutation KCNQ1-S277L.
Pacing Clin Electrophysiol,
2011
Dec
, 34 (1652-64).
865
Holme P
et al.
A generic bioanalytical method development strategy and fit-for-purpose qualification to support hERG in vitro sample analysis.
Bioanalysis,
2011
Dec
, 3 (2739-45).
866
Adeniran I
et al.
Increased vulnerability of human ventricle to re-entrant excitation in hERG-linked variant 1 short QT syndrome.
PLoS Comput. Biol.,
2011
Dec
, 7 (e1002313).
867
Trudeau MC
et al.
hERG1a N-terminal eag domain-containing polypeptides regulate homomeric hERG1b and heteromeric hERG1a/hERG1b channels: a possible mechanism for long QT syndrome.
J. Gen. Physiol.,
2011
Dec
, 138 (581-92).
868
Sung RK
et al.
QTc prolongation and family history of sudden death in a patient with desmin cardiomyopathy.
Pacing Clin Electrophysiol,
2011
Dec
, 34 (e105-8).
869
Aziz PF
et al.
Genotype- and mutation site-specific QT adaptation during exercise, recovery, and postural changes in children with long-QT syndrome.
Circ Arrhythm Electrophysiol,
2011
Dec
, 4 (867-73).
870
Shao C
et al.
Electrophysiological study of V535M hERG mutation of LQT2.
J. Huazhong Univ. Sci. Technol. Med. Sci.,
2011
Dec
, 31 (741-8).
872
Es-Salah-Lamoureux Z
et al.
Blockade of permeation by potassium but normal gating of the G628S nonconducting hERG channel mutant.
Biophys. J.,
2011
Aug
3
, 101 (662-70).
873
Giustetto C
et al.
Long-term follow-up of patients with short QT syndrome.
J. Am. Coll. Cardiol.,
2011
Aug
2
, 58 (587-95).
874
Park SJ
et al.
Bioactive sulfoximines: syntheses and properties of Vioxx analogs.
Bioorg. Med. Chem. Lett.,
2011
Aug
15
, 21 (4888-90).
875
Abassi YA
et al.
Dynamic Monitoring of Beating Periodicity of Stem Cell Derived Cardiomyocytes as a Predictive Tool for Preclinical Safety Assessment.
,
2011
Aug
12
, ().
876
Choi SH
et al.
Ginsenoside Rg(3) decelerates hERG K(+) channel deactivation through Ser631 residue interaction.
Eur. J. Pharmacol.,
2011
Aug
1
, 663 (59-67).
877
Gayen S
et al.
An NMR study of the N-terminal domain of wild-type hERG and a T65P trafficking deficient hERG mutant.
Proteins,
2011
Aug
, 79 (2557-65).
878
Sintra Grilo L
et al.
Block of the hERG channel by bupivacaine: Electrophysiological and modeling insights towards stereochemical optimization.
Eur J Med Chem,
2011
Aug
, 46 (3486-98).
879
Witchel HJ
Drug-induced hERG block and long QT syndrome.
Cardiovasc Ther,
2011
Aug
, 29 (251-9).
880
Du D
et al.
Multi-scale modeling of glycosylation modulation dynamics in cardiac electrical signaling.
Conf Proc IEEE Eng Med Biol Soc,
2011
Aug
, 2011 (104-7).
881
Fougere RR
et al.
Functional characterization of the LQT2-causing mutation R582C and the associated voltage-dependent fluorescence signal.
Heart Rhythm,
2011
Aug
, 8 (1273-80).
882
Zarraga IG
et al.
Nonsense-mediated mRNA decay caused by a frameshift mutation in a large kindred of type 2 long QT syndrome.
Heart Rhythm,
2011
Aug
, 8 (1200-6).
883
Peigneur S
et al.
A bifunctional sea anemone peptide with Kunitz type protease and potassium channel inhibiting properties.
,
2011
Apr
5
, ().
884
Wu ZY
et al.
progesterone impairs herg trafficking by disruption of intracellular cholesterol homeostasis.
,
2011
Apr
27
, ().
885
Shen MY
et al.
A Comprehensive SVM Binary hERG Classification Model Based on Extensive but Biased Endpoint hERG Data Sets.
,
2011
Apr
19
, ().
886
Fox BM
et al.
Novel pyrrolidine melanin-concentrating hormone receptor 1 antagonists with reduced hERG inhibition.
Bioorg. Med. Chem. Lett.,
2011
Apr
15
, 21 (2460-7).
887
Du CY
et al.
Pharmacological Inhibition of the hERG Potassium Channel Is Modulated by Extracellular But Not Intracellular Acidosis.
,
2011
Apr
13
, ().
888
Albesa M
et al.
Nedd4-2 dependent ubiquitylation and regulation of the cardiac potassium channel hERG.
,
2011
Apr
1
, ().
889
El Gebeily G
et al.
Upregulation of ventricular potassium channels by chronic tamoxifen treatment.
Cardiovasc. Res.,
2011
Apr
1
, 90 (68-76).
890
Windisch A
et al.
Trapping and dissociation of propafenone derivatives in HERG channels.
Br. J. Pharmacol.,
2011
Apr
, 162 (1542-52).
891
Hekkala AM
et al.
Epinephrine bolus test in detecting long QT syndrome mutation carriers with indeterminable electrocardiographic phenotype.
Ann Noninvasive Electrocardiol,
2011
Apr
, 16 (172-9).
892
Grilo LS
et al.
Patient with syncope and LQTS carrying a mutation in the PAS domain of the hERG1 channel.
Ann Noninvasive Electrocardiol,
2011
Apr
, 16 (213-8).
893
Qu Y
et al.
BeKm-1, a peptide inhibitor of human ether-a-go-go-related gene potassium currents, prolongs QTc intervals in isolated rabbit heart.
J. Pharmacol. Exp. Ther.,
2011
Apr
, 337 (2-8).
894
Kim SH
et al.
Identification of cyclicsulfonamide derivatives with an acetamide group as 11β-hydroxysteroid dehydrogenase 1 inhibitors.
Chem. Pharm. Bull.,
2011
, 59 (46-52).
895
Lahtinen AM
et al.
KCNE1 D85N polymorphism - a sex-specific modifier in type 1 long QT syndrome?
BMC Med. Genet.,
2011
, 12 (11).
896
Moric Janiszewska E
et al.
Expression of genes KCNQ1 and HERG encoding potassium ion channels Ik(r), Ik(s) in long QT syndrome.
Kardiol Pol,
2011
, 69 (423-9).
897
Chen XL
et al.
Manual whole-cell patch-clamping of the HERG cardiac K+ channel.
Methods Mol. Biol.,
2011
, 691 (151-63).
898
Kaczorowski GJ
et al.
The importance of being profiled: improving drug candidate safety and efficacy using ion channel profiling.
Front Pharmacol,
2011
, 2 (78).
899
Mihic A
et al.
Trafficking defect and proteasomal degradation contribute to the phenotype of a novel KCNH2 long QT syndrome mutation.
PLoS ONE,
2011
, 6 (e18273).
900
Sugiyama H
et al.
Circulating KCNH2 current-activating factor in patients with heart failure and ventricular tachyarrhythmia.
PLoS ONE,
2011
, 6 (e19897).
901
Ng CA
et al.
The N-terminal tail of hERG contains an amphipathic α-helix that regulates channel deactivation.
PLoS ONE,
2011
, 6 (e16191).
902
Jehle J
et al.
Novel roles for hERG K(+) channels in cell proliferation and apoptosis.
Cell Death Dis,
2011
, 2 (e193).
903
Hishigaki H
et al.
hERGAPDbase: a database documenting hERG channel inhibitory potentials and APD-prolongation activities of chemical compounds.
Database (Oxford),
2011
, 2011 (bar017).
904
Möller C
et al.
Automated electrophysiology makes the pace for cardiac ion channel safety screening.
Front Pharmacol,
2011
, 2 (73).
905
Frolov RV
et al.
Inhibition of HERG potassium channels by celecoxib and its mechanism.
PLoS ONE,
2011
, 6 (e26344).
906
Knape K
et al.
In silico Analysis of Conformational Changes Induced by Mutation of Aromatic Binding Residues: Consequences for Drug Binding in the hERG K+ Channel.
PLoS ONE,
2011
, 6 (e28778).
907
Banderali U
et al.
Curcumin Blocks Kv11.1 (erg) Potassium Current and Slows Proliferation in the Infant Acute Monocytic Leukemia Cell line THP-1.
Cell. Physiol. Biochem.,
2011
, 28 (1169-80).
908
Eldstrom J
et al.
The voltage-gated channel accessory protein KCNE2: multiple ion channel partners, multiple ways to long QT syndrome.
Expert Rev Mol Med,
2011
, 13 (e38).
909
Zhang Y
et al.
Potential therapeutic value of antioxidants for abnormal prolongation of QT interval and the associated arrhythmias in a rabbit model of diabetes.
Cell. Physiol. Biochem.,
2011
, 28 (97-102).
910
Fernández-Trillo J
et al.
Molecular determinants of interactions between the N-terminal domain and the transmembrane core that modulate hERG K+ channel gating.
PLoS ONE,
2011
, 6 (e24674).
911
Yun J
et al.
Hirsutenone directly blocks human ether-a-go-go related gene K+ channels.
Biol. Pharm. Bull.,
2011
, 34 (1815-22).
912
Li P
et al.
Novel effects of extracts from poisonous mushrooms on expression and function of the human ether-a-go-go-related gene channel.
Biol. Pharm. Bull.,
2011
, 34 (1474-80).
913
Briasoulis A
et al.
QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.
Cardiology,
2011
, 120 (103-10).
914
Kawai Y
et al.
A risk assessment of human ether-a-go-go-related gene potassium channel inhibition by using lipophilicity and basicity for drug discovery.
Chem. Pharm. Bull.,
2011
, 59 (1110-6).
915
Cordeiro S
et al.
Expression pattern of Kv11 (Ether à-go-go-related gene; erg) K+ channels in the mouse retina.
PLoS ONE,
2011
, 6 (e29490).
916
Zhang YH
et al.
Characterization of recombinant hERG K(+) channel inhibition by the active metabolite of amiodarone desethyl-amiodarone.
J Electrocardiol,
2010 Sep-Oct
, 43 (440-8).
917
Ahrendt E
et al.
Channel triage: Emerging insights into the processing and quality control of hERG potassium channels by DnaJA proteins 1, 2 and 4.
Channels (Austin),
2010 Sep-Oct
, 4 (335-6).
918
Milnes JT
et al.
Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
J Pharmacol Toxicol Methods,
2010 Mar-Apr
, 61 (178-91).
919
Himmel HM
et al.
QTc shortening with a new investigational cancer drug: a brief case study.
J Pharmacol Toxicol Methods,
2010 Jul-Aug
, 62 (72-81).
920
Wilders R
et al.
Role of the R1135H KCNH2 mutation in Brugada syndrome.
Int. J. Cardiol.,
2010
Sep
24
, 144 (149-51).
921
Yasuda S
et al.
A family of hereditary long QT syndrome caused by Q738X HERG mutation.
Int. J. Cardiol.,
2010
Sep
24
, 144 (69-72).
922
Haugaa KH
et al.
Transmural Differences in Myocardial Contraction in Long-QT Syndrome. Mechanical Consequences of Ion Channel Dysfunction.
,
2010
Sep
20
, ().
923
Ren XQ
et al.
Pore Mutants of HERG and KvLQT1 Downregulate the Reciprocal Currents in Stable Cell Lines.
,
2010
Sep
10
, ().
924
Perry M
et al.
Revealing the structural basis of action of hERG potassium channel activators and blockers.
J. Physiol. (Lond.),
2010
Sep
1
, 588 (3157-67).
925
Bokil NJ
et al.
Molecular genetics of long QT syndrome.
Mol. Genet. Metab.,
2010
Sep
, 101 (1-8).
926
Mathie A
Ion channels as novel therapeutic targets in the treatment of pain.
J. Pharm. Pharmacol.,
2010
Sep
, 62 (1089-95).
927
Zünkler BJ
et al.
Comparison of the effects of methadone and heroin on human ether-à-go-go-related gene channels.
Cardiovasc. Toxicol.,
2010
Sep
, 10 (161-5).
928
Lazzerini PE
et al.
Anti-Ro/SSA antibodies and cardiac arrhythmias in the adult: facts and hypotheses.
Scand. J. Immunol.,
2010
Sep
, 72 (213-22).
929
Shao L
et al.
Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.
,
2010
Oct
28
, ().
930
Shim WS
et al.
An aqueous extract of Poncirus fructus activates the prokinetic activity of 5-HT receptor subtype 4 without hERG interaction.
J Ethnopharmacol,
2010
Oct
28
, 132 (328-33).
931
Papadatos G
et al.
Lead optimization using matched molecular pairs: inclusion of contextual information for enhanced prediction of HERG inhibition, solubility, and lipophilicity.
J Chem Inf Model,
2010
Oct
25
, 50 (1872-86).
932
Zhou J
et al.
Effect of Lead Ion on the Function of the Human Ether-À-Go-Go-Related Gene K(+) Channel.
,
2010
Oct
2
, ().
933
Gong Q
et al.
Alternative splicing and polyadenylation contribute to the generation of hERG1 C-terminal isoforms.
J. Biol. Chem.,
2010
Oct
15
, 285 (32233-41).
934
Tester DJ
et al.
Prevalence and spectrum of large deletions or duplications in the major long QT syndrome-susceptibility genes and implications for long QT syndrome genetic testing.
Am. J. Cardiol.,
2010
Oct
15
, 106 (1124-8).
935
Liu Y
et al.
9-Dihydroerythromycins as non-antibiotic motilin receptor agonists.
Bioorg. Med. Chem. Lett.,
2010
Oct
1
, 20 (5658-61).
936
Li Q
et al.
1H, 13C and 15N chemical shift assignments for the N-terminal domain of the voltage-gated potassium channel-hERG.
Biomol NMR Assign,
2010
Oct
, 4 (211-3).
937
Wu HJ
et al.
Effect of matrine on human ether à go-go related gene (HERG) channels expressed in Chinese hamster ovary cells.
Chin J Integr Med,
2010
Oct
, 16 (430-4).
938
Larsen AP
Role of ERG1 isoforms in modulation of ERG1 channel trafficking and function.
Pflugers Arch.,
2010
Oct
, 460 (803-12).
939
Larsen AP
et al.
Differential effects of Kv11.1 activators on Kv11.1a, Kv11.1b and Kv11.1a/Kv11.1b channels.
Br. J. Pharmacol.,
2010
Oct
, 161 (614-28).
940
Jeong I
et al.
Effects of lobeline, a nicotinic receptor ligand, on the cloned Kv1.5.
Pflugers Arch.,
2010
Oct
, 460 (851-62).
941
Hondeghem LM
et al.
Oscillations of cardiac wave length and proarrhythmia.
Naunyn Schmiedebergs Arch. Pharmacol.,
2010
Oct
, 382 (367-76).
942
Du CY
et al.
Acidosis impairs the protective role of hERG K(+) channels against premature stimulation.
J. Cardiovasc. Electrophysiol.,
2010
Oct
, 21 (1160-9).
943
Zhang XH
et al.
The calmodulin inhibitor N-(6-aminohexyl)-5-chloro-1-naphthalene sulphonamide directly blocks human ether à-go-go-related gene potassium channels stably expressed in human embryonic kidney 293 cells.
Br. J. Pharmacol.,
2010
Oct
, 161 (872-84).
944
Abela D
et al.
The effect of drugs with ion channel-blocking activity on the early embryonic rat heart.
Birth Defects Res. B Dev. Reprod. Toxicol.,
2010
Oct
, 89 (429-40).
945
Lian J
et al.
Novel characteristics of a trafficking-defective G572R-hERG channel linked to hereditary long QT syndrome.
Can J Cardiol,
2010
Oct
, 26 (417-22).
946
Kuryshev YA
et al.
Increased cardiac risk in concomitant methadone and diazepam treatment: pharmacodynamic interactions in cardiac ion channels.
J. Cardiovasc. Pharmacol.,
2010
Oct
, 56 (420-30).
947
Sordel T
et al.
The development of high quality seals for silicon patch-clamp chips.
Biomaterials,
2010
Oct
, 31 (7398-410).
948
Kim MJ
et al.
High-content screening of drug-induced cardiotoxicity using quantitative single cell imaging cytometry on microfluidic device.
,
2010
Nov
8
, ().
949
Angus D
et al.
The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.
,
2010
Nov
6
, ().
950
Van Slyke AC
et al.
Mutations within the S4-S5 linker alter voltage sensor constraints in hERG K+ channels.
Biophys. J.,
2010
Nov
3
, 99 (2841-52).
951
Oka Y
et al.
Atrioventricular block-induced Torsades de Pointes with clinical and molecular backgrounds similar to congenital long QT syndrome.
Circ. J.,
2010
Nov
25
, 74 (2562-71).
952
953
Pryde DC
et al.
An in situ oxidation strategy towards overcoming hERG affinity.
Bioorg. Med. Chem. Lett.,
2010
Nov
15
, 20 (6400-4).
954
Anderson JT
et al.
Investigation of 4-piperidinols as novel H3 antagonists.
Bioorg. Med. Chem. Lett.,
2010
Nov
1
, 20 (6246-9).
955
Rankovic Z
et al.
Optimisation of 2-cyano-pyrimidine inhibitors of cathepsin K: improving selectivity over hERG.
Bioorg. Med. Chem. Lett.,
2010
Nov
1
, 20 (6237-41).
956
Liu Y
et al.
9-Dihydroerythromycin ethers as motilin agonists--developing structure-activity relationships for potency and safety.
Bioorg. Med. Chem.,
2010
Nov
1
, 18 (7651-8).
957
Subbotina J
et al.
Structural refinement of the hERG1 pore and voltage-sensing domains with ROSETTA-membrane and molecular dynamics simulations.
Proteins,
2010
Nov
1
, 78 (2922-34).
958
Sy RW
et al.
Repolarization dynamics during exercise discriminate between LQT1 and LQT2 genotypes.
J. Cardiovasc. Electrophysiol.,
2010
Nov
, 21 (1242-6).
959
Doddareddy MR
et al.
Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases.
ChemMedChem,
2010
May
3
, 5 (716-29).
960
Yan L
et al.
Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
J. Med. Chem.,
2010
May
27
, 53 (4028-37).
961
Kang J
et al.
In Vitro Electrocardiographic and Cardiac Ion Channel Effects of (-)-Epigallocatechin-3-Gallate, the Main Catechin of Green Tea.
,
2010
May
18
, ().
962
Klon AE
Machine learning algorithms for the prediction of hERG and CYP450 binding in drug development.
,
2010
May
14
, ().
963
Palmer AM
et al.
Tetrahydrochromenoimidazoles as potassium-competitive acid blockers (P-CABs): structure-activity relationship of their antisecretory properties and their affinity toward the hERG channel.
J. Med. Chem.,
2010
May
13
, 53 (3645-74).
964
Chen J
et al.
Post-transcriptional control of HERG potassium channel protein by {alpha}-adrenergic receptor stimulation.
,
2010
May
12
, ().
965
Leong IU
et al.
Identification and expression analysis of kcnh2 genes in the zebrafish.
,
2010
May
10
, ().
966
Lavrador-Erb K
et al.
The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.
Bioorg. Med. Chem. Lett.,
2010
May
1
, 20 (2916-9).
967
Gu SJ
et al.
Synthesis and biological evaluation of 1,4-diazepane derivatives as T-type calcium channel blockers.
Bioorg. Med. Chem. Lett.,
2010
May
1
, 20 (2705-8).
968
Allegue C
et al.
A new approach to long QT syndrome mutation detection by Sequenom MassARRAY system.
Electrophoresis,
2010
May
, 31 (1648-55).
969
Kim KS
et al.
Blockade of hERG K(+) channel by antimalarial drug, primaquine.
Arch. Pharm. Res.,
2010
May
, 33 (769-73).
970
Obers S
et al.
Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine.
Naunyn Schmiedebergs Arch. Pharmacol.,
2010
May
, 381 (385-400).
971
Möller C
Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology.
Expert Rev Clin Pharmacol,
2010
May
, 3 (321-9).
972
Beacham DW
et al.
Cell-Based Potassium Ion Channel Screening Using the FluxORTM Assay.
,
2010
Mar
5
, ().
973
Porthan K
et al.
Relationship of Common Candidate Gene Variants to Electrocardiographic T-Wave Peak to T-Wave End Interval and T-Wave Morphology Parameters.
,
2010
Mar
4
, ().
974
975
Xing J
et al.
Block effect of capsaicin on hERG potassium currents is enhanced by S6 mutation at Y652.
Eur. J. Pharmacol.,
2010
Mar
25
, 630 (1-9).
976
Stary A
et al.
Toward a consensus model of the HERG potassium channel.
ChemMedChem,
2010
Mar
1
, 5 (455-67).
977
Amin AS
et al.
Fever-triggered ventricular arrhythmias in Brugada syndrome and type 2 long-QT syndrome.
Neth Heart J,
2010
Mar
, 18 (165-9).
978
Itoh H
et al.
Long QT Syndrome with Compound Mutations is Associated with a More Severe Phenotype :A Japanese Multicenter Study.
,
2010
Jun
8
, ().
979
Butini S
et al.
Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.
J. Med. Chem.,
2010
Jun
24
, 53 (4803-7).